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“One never knows, what awaits one “
Laurie Lee 1936
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Introduction: The pathogenesis of diabetic nephropathy remains a matter of 
debate, although strong evidence suggests that it results from the interaction 
between susceptibility genes and the diabetic milieu. The true pathogenetic 
mechanism remains unknown, but a common denominator of micro- and 
macrovascular complications may exist. Some have suggested that the 
renal analogue to the inflammatory process observed in atherosclerosis is 
glomerusclerosis. Others have also suggested that activation of the complement 
system contributes to the cascade of inflammation. Defensins, as part of the 
innate immune system, may play a regulatory role in the complement cascade and 
augment the production of proinflammatory cytokines. Adiponectin, a hormone 
secreted by the adipocytes, has been associated with both insulin-sensitizing and 
anti-inflammatory properties, and the concentration of adiponectin has proved to 
be consistently higher in patients with non-diabetic renal disease than in healthy 
control subjects, even if such patients display insulin resistance and an increased 
risk for cardiovascular disease. 
Aims of the study: The present studies were undertaken to investigate whether 
low-grade inflammation, mannan-binding lectin (MBL) and α-defensin play a 
role, together with adiponectin, in patients with type 1 diabetes and diabetic 
nephropathy. 
Subjects and methods: This study is part of the ongoing Finnish Diabetic 
Nephropathy Study (FinnDiane). The first four cross-sectional substudies of this 
thesis comprised 194 patients with type 1 diabetes divided into three groups 
(normo-, micro-, and macroalbuminuria) according to their albumin excretion 
rate (AER) in two of three consecutive overnight or 24-hour urine collections. The 
fifth substudy aimed to determine whether baseline serum adiponectin plays a 
role in the development and progression of diabetic nephropathy. This follow-up 
study included 1330 patients with type 1 diabetes and a mean follow-up period 
of five years. The patients were divided into three groups depending on their 
AER at baseline. As a measure of low-grade inflammation, highly sensitive CRP 
(hsCRP) and α-defensin were measured with radio-immunoassay, and interleukin-6 
(IL-6) with high- sensitivity enzyme immuno-assay. Mannan-binding lectin and 
adiponectin were determined with time-resolved immunofluorometric assays. The 
progression of albuminuria from one stage to the other served as a measure of 
the progression of diabetic nephropathy. 
Results: Low-grade inflammatory markers, MBL, adiponectin, and α-defensin 
were all associated with diabetic nephropathy, whereas MBL, adiponectin, and 
α-defensin per se were unassociated with low-grade inflammatory markers. 
hsCRP was higher in patients with micro- or macroalbuminuria than in those with 
normoalbuminuria. AER was the only clinical variable independently associated 
with hsCRP. IL-6 increased in parallel with the severity of renal disease, whereas 
AER, HDL-cholesterol and the duration of diabetes were independently associated 
with IL-6. MBL was higher in patients with micro- or macroalbuminuria than in 
those with normoalbuminuria, but no difference was observed between those 
with micro- and macroalbuminuria. HbA1c was the only variable independently 
associated with MBL. Adiponectin increased in parallel with the severity of diabetic 
nephropathy. The estimated glomerular filtration rate (eGFR), AER, and waist-to-
hip ratio were independently associated with adiponectin. α-defensin was lower in 
patients with normo- and microalbuminuria than in those with macroalbuminuria, 
and systolic blood pressure, HDL-cholesterol, total cholesterol, age, and eGFR were 
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all independently associated with α-defensin. In patients with macroalbuminuria, 
progression to end-stage renal disease (ESRD) was associated with higher 
baseline adiponectin concentrations, but no differences were observed between 
progressors and non-progressors in patients with normo- or microalbuminuria. 
In addition to adiponectin, progression to ESRD was also associated with HbA1c, 
triglycerides, and eGFR. 
Discussion and conclusions: Low-grade inflammation, MBL, adiponectin, and 
defensin were all associated with diabetic nephropathy in these cross-sectional 
studies. In contrast however, MBL, adiponectin, and defensin were not associated 
with low-grade inflammatory markers per se. Nor was defensin associated with 
MBL, which may suggest that during the acute phase response, these different 
players function in a coordinated fashion during the deleterious process of diabetic 
nephropathy. 
The question of what causes low-grade inflammation in patients with type 1 
diabetes and diabetic nephropathy, however, remains unanswered. Potential 
causative factors may include susceptibility genes, obesity, hyperglycemia, 
hyperlipidemia, smoking, and a low level of physical activity. To support this 
suggestion we could in our study observe that glycemic control, an atherosclerotic 
lipid profile, and waist-to-hip ratio (WHR) were associated with low-grade 
inflammation in the univariate analysis, although in the multivariate analysis, 
only AER, HDL-cholesterol, and the duration of diabetes, as a measure of glycemic 
load, proved to be independently associated with inflammation. Notably, all 
these factors, except the genes, are modifiable with changes in lifestyle or with a 
targeted medication or both. In the follow-up study, elevated serum adiponectin 
levels at baseline predicted the progression from macroalbuminuria to ESRD 
independently of renal function at baseline. This observation does not preclude 
adiponectin as a favorable factor during the process of diabetic nephropathy, since 
the rise in serum adiponectin concentrations may remain a mechanism by which 
the body compensates for the demands created by the diabetic milieu.
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1. Introduction
The discovery of insulin 1921 and its industrialized production made it 
possible to save the lives of thousands of patients with type 1 diabetes 
already during the first years of injectable insulin (1). At that time, 
knowledge of future secondary complications in the eyes and kidneys as 
well as their association with long-lasting high blood glucose was scarce. 
Even so, during the first two decades of the insulin era, people with type 1 
diabetes lived long enough to develop complications.
As early as 1936, Paul Kimmelstiel and Clifford Wilson described 
structural changes in the kidneys and the clinical picture of diabetic 
kidney disease (diabetic nephropathy) (2). Evidence-based knowledge has 
since accumulated and has highlighted the importance of strict glycemic 
and blood pressure control in the avoidance and treatment of diabetic 
nephropathy. The goals of such treatment have changed in parallel with 
emerging new evidence, and fortunately treatment options have also 
improved in parallel with stricter targets for glycemic and blood pressure 
control. Despite all this positive development, epidemiological studies have 
demonstrated that during the past three decades, diabetic nephropathy 
continues to occur in 15-40% of patients with type 1 diabetes with a peak 
incidence after 15 to 20 years of diabetes (3, 4, 5). Diabetic nephropathy is 
the most common cause of renal failure in the industrialized world (6, 7). In 
addition, diabetic nephropathy is also strongly associated with premature 
cardiovascular mortality (8, 9, 10). 
The pathogenesis of diabetic nephropathy remains somewhat unclear, 
but evidence suggests that it results from an interaction between 
susceptibility genes and the diabetic milieu.
Due to the strong association between diabetic nephropathy and 
macrovascular disease, some researchers have suggested a common 
denominator may link micro- and macrovascular complications. One such 
factor could be chronic low-grade inflammation (11, 12).
The present studies were therefore undertaken to explore the possible 
role of inflammation, mannan-binding lectin, adiponectin, and defensin in 
the deleterious process leading to diabetic nephropathy.
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2. Review of the literature
2.1 Definition, diagnosis and classification of diabetes
2.1.1 Definition of diabetes 
Diabetes is a systemic disease characterized by chronic hyperglycemia and 
disturbances in carbohydrate, lipid, and protein metabolism. Diabetes is the 
consequence of a decrease in insulin secretion or in the activity of insulin, 
or both. The diabetic syndromes represent a diverse clinical spectrum. 
Diabetes may present with characteristic symptoms such as thirst, polyuria, 
and weigth loss, but its most severe manifestations are ketoacidosis or 
nonketotic hyperosmolaric coma. The symptoms are often vague or may 
even be absent altogether(13).
Diabetes is a universal chronic disease with widely varying prevalence 
rates across different populations. All over the world, the prevalence rates 
of diabetes are increasing, and in the latest IDF ATLAS, northern Europe had 
a 7% prevalence of diabetes in the adult population, while corresponding 
rates were already 8% in the US and 9% in China (14).
2.1.2 Diagnosis of diabetes 
The WHO has established criteria for the diagnosis of diabetes mellitus (15). 
If a patient presents symptoms such as thirst, polyuria and weight loss, the 
diagnosis can be established by demonstrating fasting hyperglycemia. If the 
fasting plasma glucose falls within the diagnostic range for diabetes (> 6.9 
mmol/l), no oral glucose tolerance test (OGTT) is required for the diagnosis. 
On the other hand, if the patient presents only minimal symptoms or the 
fasting plasma glucose concentration is within the normal range, an OGTT 
is required to confirm the diagnosis of diabetes. 
2.1.3 Classification of diabetes 
The classification of diabetes is based on the etiology of the disease, even if 
the true etiology and pathogenesis of the two most common remains only 
partially understood (15). The clear majority of cases falls into two broad 
etiopathogenetic categories, called type 1 and type 2 diabetes, although the 
extent of heterogeneity among these two types remains uncertain. The third 
category of diabetes includes nongenetic forms secondary to pancreatitis, 
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pancreas cancer, or a number of endocrine entities on the one hand, and 
monogenic forms of diabetes on the other. Monogenic diabetes comprises 
genetic defects in beta cell function, the most common form of which 
is known as MODY, or maturity onset diabetes of the young. The fourth 
category of diabetes is called gestational diabetes, and is characterized by 
carbohydrate intolerance and hyperglycemia of variable severity with onset 
during pregnancy.
2.2 Diabetic complications 
Diabetes has wide-ranging effects on metabolism, and a long-term disease 
such as diabetes may have several potential mediators of tissue damage. The 
consequences of such tissue damage may include the dysfunction and total 
failure of various organs, especially the eyes, kidneys, heart, feet, and blood 
vessels. One explanation for the development of long-term complications 
of diabetes is the failure of antidiabetic therapy to normalize metabolism 
completely. 
The prevalence of microangiopathic complications such as retinopathy, 
neuropathy, and nephropathy was the highest in patients with poor 
glycemic control in a 25-year follow-up study in a large cohort of patients 
with both type 1 and type 2 diabetes (16). This observation later proved 
to be true also despite more modern treatment options in the DCCT study 
in patients with type 1 diabetes and in the UKPDS in patients with type 2 
diabetes (17, 18). 
It is worth noting that in these studies, some patients presented no 
complications even though they had chronically poor metabolic control. 
Regarding nephropathy, this interesting escape phenomenon was associated 
with low blood pressure, thus supporting the role of concomitant poor 
glycemic control and elevated blood pressure for the development of 
diabetic nephropathy and possibly also for retinopathy (19, 20). 
Patients with either type 1 or type 2 diabetes are at increased risk for 
atherosclerotic, macrovascular disease. Macroangiopathy and cardiovascular 
disease account for 70-75% of deaths in people with diabetes (21). The 
clinical picture related to the etiopathogenesis of macrovascular disease 
includes several abnormalities such as hyperlipidemia, hypertension, 
hyperglycemia and insulin resistance. 
Patients with diabetic nephropathy and non-diabetic patients 
with already diagnosed macroangiopathy share the same risk factors 
for cardiovascular disease, as as well as the risk of early death from 
cardiovascular disease is also greatly increased (8, 9).
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2.2.1 Diabetic nephropathy
2.2.1.1	 Definitions
Diabetic nephropathy is defined as a progressive increase in the urinary 
albumin excretion rate accompanied by increasing blood pressure and a 
relentless decline in the glomerular filtration rate with end-stage renal 
failure as the final endpoint (22). Diabetic nephropathy is typically 
accompanied by retinopathy. Many people with diabetes do not necessarily 
progress to end-stage renal disease (ESRD), as they may die before then 
from cardiovascular disease (8, 9). 
The different stages of diabetic nephropathy are classified according to 
the increase in the urinary albumin excretion rate in timed urine collections 
either overnight or during a 24-h period. Microalbuminuria is defined as 
an increase in the AER above normal (i.e. ≥ 20 µg/min or ≥ 30 mg/24 h). 
Proteinuria represents an increase in albuminuria of ≥ 200 µg/min or ≥ 300 
mg/24 h. When daily proteinuria exceeds 3 g, the patient is deemed to have 
nephrotic syndrome. The final stage of diabetic nephropathy is ESRD. To be 
classified as microalbuminuric or proteinuric, the patient’s AER must exceed 




At diagnosis of type 1 diabetes, patients typically exhibit an elevated 
AER and display glomerular hyperfiltration. However, the AER returns to 
normal after the initiation of insulin treatment, and the same change occurs 
regarding the glomerular filtration rate (GFR) in most patients (23-27). 
The transition from normoalbuminuria to microalbuminuria has been 
associated with the baseline AER, blood glucose control, blood pressure, 
and the presence of retinopathy (22). 
Some studies have suggested that the prevalence of microalbuminuria, 
incipient diabetic nephropathy, has been relatively high, even as high as 
19% of patients, during the first five years of type 1 diabetes (28, 29), 
whereas other studies, show that the AER remained normal during these 
initial years (26, 27). 
The proportion of patients with microalbuminuria has been reported 
to increase during the first decades of diabetes. In a large-scale European 
study, the prevalence of microalbuminuria was 31% after 15 years (28), and 
27% after 15-29 years of type 1 diabetes in Northern Wales (30). In Sweden, 
the prevalence rates for microalbuminuria have been considerably lower: 
only 6% in patients diagnosed at the beginning of the 1970s and followed 
for 20 years (31). The reason for the discrepancy between the Swedish and 
the other studies may be strongly associated with the significantly better 
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glycemic control in the Swedish patients than in the patients in the other 
studies. 
In previous studies approximately 80% of the patients with 
microalbuminuria developed proteinuria (32, 33). In more recent studies, 
however, only about 20% of microalbuminuric patients progress to 
overt proteinuria over a period of ten years, whereas 50% remain 
microalbuminuric, and 30% regress to normoalbuminuria (27, 34). The risk 
for progression from microalbuminuria to overt nephropathy is strongly 
associated with blood pressure (34). 
When a patient has progressed to persistent proteinuria, his/her 
urinary protein excretion rate rises continuously and, as in the stage of 
microalbuminuria, the blood pressure becomes a particularly important 
determinant of this process (35). 
Renal	function	
At the moment the patient presents with persistent proteinuria, the GFR 
will begin to decline. Because blood pressure is the key determinant of the 
progression of the disease the average fall in the GFR will be approximately 
10-12 ml/min annually, if the hypertension goes untreated. Thus the 
progression of the disease from the onset of proteinuria to the inevitable 
ESRD will take roughly 8-10 years (36-38). However, efficient treatment and 
the normalization of blood pressure will retard the disease process and 
postpone the development of ESRD (39-41). 
Blood	pressure	
Blood pressure rises in parallel with the increase in the urinary albumin 
excretion rate, and if blood pressure goes untreated, over 80% of the 
patients with proteinuria will have blood pressure exceeding 140/90 mmHg. 
It thus comes as no surprise that hypertension is an essential component of 
the clinical picture in patients with ESRD (22).
2.2.1.3	 Prevention	of	diabetic	nephropathy
Primary	prevention
The landmark DCCT study demonstrated that good glycemic control can 
considerably reduce the risk for micro- and macroalbuminuria. In patients 
with normoalbuminuria at baseline, the reduction in the relative risk 
for developing microalbuminuria was 39% , and that for developing 
proteinuria, 54% in those patients with an HbA1c of 7% compared to those 
with an HbA1c of 9%. The study showed that the lower the HbA1c, the lower 
the risk (42).
Secondary	prevention
Once microalbuminuria or proteinuria has become manifest, there is no solid 
evidence of a benefit of good glycemic control; there is, however, abundant 
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evidence that the reduction of blood pressure can slow the progression 
of micro- and macroalbuminuria to ESRD (43, 44). Angiotensin-converting 
enzyme (ACE) inhibitors are preferred as the first-line treatment in patients 
with type 1 diabetes and nephropathy (45), since ACE inhibitors reduce 
the albumin excretion rate more than do other classes of antihypertensive 
agents (46). Furthermore, this renoprotective effect is independent of blood 
pressure reduction and may be related to reduced intraglomerular pressure 
and the passage of proteins into the proximal tubule (47, 48). The reduction 
of blood pressure to < 140/80 mmHg, which is still a rather conservative 
level, has proved capable of reducing the decline in GFR from 10-12 ml/min 
per year without treatment to 1 ml/min per year in patients with reasonably 
good glycemic control and low cholesterol (44). However, most patients with 
proteinuria reguire multiple agents in addition to ACE inhibitors to achieve 
a new blood pressure target of < 130/80 mmHg (49). 
2.2.1.4	 Pathogenesis	of	diabetic	nephropathy
The specific pathology of diabetic nephropathy is restricted mainly to 
the renal glomeruli and the tubular interstitium (50). Histologically, the 
hallmarks of diabetic nephropathy include thickening of the glomerular 
basement membrane and an increase in the fractional volume of the 
mesangium (51). Expansion of the glomerular mesangium correlates closely 
with a reduced renal function and the development of proteinuria (52). 
During the progression of the disease, mesangial expansion typically 
presents as nodular glomerular lesions. For diabetic nephropathy, these 
pathognomonic lesions bear the name Kimmelstiel-Wilson nodules according 
to their first description by Kimmelstiel and Wilson (2). 
The tubulointerstitial injury appears to be closely associated to the 
glomerular pathology. Interstitial expansion is related to renal dysfunction, 
proteinuria, and mesangial expansion (53). 
Patients with type 1 diabetes and microalbuminuria typically exhibit an 
increased fractional volume of the mesangium, an observation which maybe 
associated with a rise in blood pressure and a small reduction in creatinine 
clearance (54, 55). In patients with macroalbuminuria, the expansion of 
the mesangium and the interstitium, together with glomerular occlusions, 
closely correlate with a reduced renal function (50). 
2.2.1.5	 Pathogenic	mechanisms	of	diabetic	nephropathy
Hyperglycemia
As described above, poor glycemic control has been shown to contribute 
to the development of micro- and macroalbuminuria. Intensive glucose 
control, HbA1c 7% vs 9%, reduces the risk for progression from normo- to 
microalbuminuria in patients with type 1 diabetes (42).
Hyperglycemia has also been linked to many deleterious processes in 
renal tissue. High glucose in the mesangial cells induces cell hypertrophy 
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and increases the extracellular matrix deposits by stimulating the expression 
of various genes and protein secretion, such as collagen and fibronectin 
(56, 57). Furthermore, hyperglycemia has been shown to stimulate the 
transforming growth factor (TGF)-β system, and the induction of this system 
is considered to be one of the main determinants of hypertrophy of the 
mesangial and tubular cells in diabetic nephropathy (58).
Sustained hyperglycemia leads to enhanced non-enzymatic protein 
glycation, which represents the increased covalent binding of glucose to 
proteins. The process of glycation progresses via relatively stable ketoamines, 
products of Amadori, to stable advanced glycation end-products (AGEs). 
AGEs accumulate in the tissues over the lifetime of the protein (59). In 
patients with diabetes, AGEs accumulate in renal glomeruli and tubuli (60). 
AGEs have been shown to affect properties of extracellular matrix proteins 
leading to matrix rigidity and mesangial expansion (61).
The enzyme aldose reductase via the polyol pathway, reduces glucose 
to sorbitol. In chronic hyperglycemia sorbitol accumulates in many tissues, 
including the renal glomeruli and tubuli. Some have suggested that this 
accumulation of sorbitol is deleterious to the renal tissue by disturbing 
cellular osmoregulation and by changing the cellular redox potential (62, 
63). In addition, inhibition of the enzyme aldose reductase has been shown 
to prevent a glucose-induced increase in TGF-β1 production and protein 
kinase C (PKC) activity in human mesangial cells (64). Aldose reductase 
inhibitors have not yet been introduced as the treatment of choice for 
human diabetic nephropathy, since clinical trials have not only proved 
ineffective, but also caused adverse effects on many of the potential 
inhibitors tested in recent years (65). 
The hexoasamine pathway, another of the intracellular pathways of 
glucose metabolism, also appears to be related to diabetic complications 
(66). Activation of this pathway during hyperglycemia has been linked to 
diabetic nephropathy through its end-product, N-acetylglucosamine, which 
in turn is associated with increased TGF-β1 expression (67). 
Hyperglycemia is also associated with oxidative stress through the 
increased production of reactive oxygen species (68-70). Oxidative stress 
and its concomitant, reactive oxygen species, are not only recognized as 
one of the most important components in the pathogenesis of diabetic 
microvascular complications, but also as a possible unifying mechanism in 
the pathogenesis of both microvascular and macrovascular complications 
(71, 72). High glucose in diabetic cells induces the production of superoxide, 
which is deleterious to the cells by activation of the polyol and hexosamine 
pathways, the formation of AGEs, and the activation of PKC (72). 
Hypertension
In patients with diabetes, the development of proteinuria is typically 
parallelled by an increase in systemic blood pressure, and blood pressure is 
further closely related to a decline in the glomerular filtration rate (73). In 
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patients with type 1 diabetes and normoalbuminuria, blood pressure has 
been shown to be already higher in those who progress to microalbuminuria 
than in patients with stable normoalbuminuria, even if the mean systemic 
blood pressure in the progressors was no higher than a mean of 138/82 
mmHg (74). 
Glycemic control is also linked to high blood pressure, since vasodilatation, 
induced by hyperglycemia, reduces afferent arteriolar resistance in the 
glomerulus proportionally more than efferent arteriolar resistance. The net 
effect is an increase in glomerular capillary pressure level. In the presence 
of hyperglycemia, even a small increase in systemic blood pressure may thus 
be deleterious to the hemodynamics of the glomerulus (75). 
Increased glomerular capillary pressure and concomitant glomerular 
expansion are associated with a stretching of its components. Stretch in the 
mesangial cells leads in turn to stimulation of the synthesis and deposition 
of matrix components (76).
Proteinuria
Proteinuria is a key factor in diabetic nephropathy and a predictor of 
progression to ESRD, and has even been suggested as an important factor 
per se in promoting the progression of diabetic nephropathy (77, 78). 
Excessive protein overload leads to tubulointerstitial damage by inducing 
the release of chemokines and endothelin (79-81). The beneficial effect of 
ACE-inhibition in diabetic nephropathy has at least partly been associated 
with its effect on proteinuria (46). 
2.2.1.6	 Signaling	pathways	and	mediators	of	diabetic	nephropathy
Several cytokines have been associated with the pathophysiology of diabetic 
nephropathy, particularly TGF-β1 (82). Increased TGF-β1 expression has been 
demonstrated in an animal model of diabetic kidney disease (rat model) 
and in patients with type 2 diabetes and diabetic nephropathy (83, 84). 
Hyperglycemia stimulates TGF-β1 expression in a variety of renal cells, such 
as glomerular mesangial cells and renal interstitial fibroblasts (85). TGF-β1 
increases matrix synthesis as well as inhibits its degradation, and has also 
been associated with the upregulation of adhesion molecules and enhanced 
chemoattraction (86, 87).
Connective tissue growth factor (CTGF) is another cytokine that has been 
associated with diabetic nephropathy (88, 89). High glucose and TGF-β1 
induce CTGF expression in mesangial cells, and CTGF in turn mediates TGF-
β1-induced fibroblast collagen synthesis (88-90). 
Circulating and local vascular endothelial growth factor (VEGF) levels are 
high in diabetes, and an excess of VEGF plays a role in mediating glomerular 
hypertrophy and proteinuria (91, 92). Excessive angiogenesis, induced by 
VEGF, has even been linked to the progression of diabetic nephropathy 
(93, 94).
In the kidney high glucose has been associated with an activation of a 
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local renin-angiotensin system in the mesangial cells, the proximal tubular 
cells and the podocytes (95-97). Angiotensin-2 stimulates the expression of 
TGF-β1 in the kidney. Thus hemodynamic as well as structural changes in 
diabetic nephropathy are suggested to result from the interplay between 
angiotensin-2 and TGF-β1, and angiotensin-2 even plays a role in the 
progression of diabetic nephropathy (98). 
The growth hormone-insulin-like growth factor-insulin growth factor-
binding protein (GH-IGF-IGFBP) axis has been suggested both to maintain 
normal renal function and to play an important role in the development 
of DN (99). These growth factors are linked to the earliest detectable renal 
changes associated with hyperglycemia (100, 101). The kidney is a site for 
the production of IGF-1, which normally mediates its effects on renal growth 
and function (102, 103). In diabetes the expression of IGF-1 in the kidneys 
increases, and furthermore, the upregulation of IGF-binding proteins has 
been implicated in IGF-1 trapping in the kidney (104). In cell cultures, IGF-1 
has been shown to induce mesangial proliferation and the secretion of 
collagen (105). Recently IGFBP-3, one of the IGF-binding proteins, has been 
associated with podocyte apoptosis (99). 
Protein kinase C, PKC, a family of many serine-threonine kinases, is 
activated by diacylglycerol (DAG) (106). Concentrations of DAG typically 
increase in diabetes due to hyperglycemia (107-109). The activation of PKC 
is present in many different tissues, such as the glomeruli, and a variety of 
functional abnormalities may result from the activation of the DAG-PKC 
pathway in the renal tissue also (110, 111). PKC has been shown to mediate 
the intracellular signals of TGF-β1, VEGF, and angiotensin-2, and PKC is 
further suggested to be a major signaling pathway for TGF- β in inducing 
extracellular matrix production in diabetic nephropathy (111-113). The 
activation of PKC further activates mitogen-activated protein kinase (MAPK) 
to form the DAG-PKC-MAPK pathway, a transduction system of signals 
from hyperglycemic plasma to the glomerular cell nucleus in patients with 
diabetic nephropathy. The high expression of the DAG-PKC-MAPK mRNA has 
accordingly been suggested to play an important role in the pathogenesis 
of diabetic nephropathy (113).
2.2.1.7	 Genetics	of	diabetic	nephropathy	in	type	1	diabetes
The familial clustering of diabetic nephropathy suggests that genetic factors 
are important in determining susceptibility (114, 115). The cumulative 
incidence of diabetic nephropathy among siblings with type 1 diabetes 
who have a proband with type 1 diabetes and diabetic nephropathy is 
approximately 70% compared to 25% among diabetic siblings with a 
proband unaffected by diabetic nephropathy (116). A family history of 
hypertension has also been associated with increased predisposition to 
diabetic nephropathy (117). In Finland, a family history of type 2 diabetes 
was also associated with the risk for diabetic nephropathy in family members 
with type 1 diabetes (118).
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2.2.1.8	 Birth	weight	and	diabetic	nephropathy	in	patients	with	type	1	
diabetes
Low birth weight has been suggested to confer increased risk for diabetic 
nephropathy in patients with both type 1 diabetes (119) and type 2 diabetes 
(120). The association between low birth weight and diabetic nephropathy 
in patients with type 1 was observed only in females (119), but in the 
Pima Indian population with type 2 diabetes, there was no sex-specific 
effect (120). In contrast, cross-sectional data from Finland in a Caucasian 
population of 1543 patients with type 1 diabetes, suggested no role for low 
birth weight in the development of diabetic nephropathy (121)
2.3 Immune defense systems 
2.3.1 Adaptive and innate immunity 
The antimicrobial defense system is generally divided into acquired 
(adaptive) immunity and innate immunity (122). The acquired immune 
system uses B- and T-lymphocytes to mediate antigen-specific humoral and 
cellular responses. These responses require a relatively long period of time, 
from days to weeks, for maximal activity and also result in immunologic 
memory. The function of the system is intimately tied to the innate immune 
system (123-125). 
The innate immune system depends on non-lymphoid tissue and is 
phylogenetically older than acquired immunity. The innate immune 
system is a first-line defense system which uses soluble and cellular sensing 
mechanisms to recognise potentially harmful substances (122, 126). The 
innate immune system is fast and immediately inducible in comparison 
to the slower acquired immune system. The various elements of innate 
immunity do not function in isolation, but interact to ensure that the 
magnitude of the host response reflects the severity of the foreign threat 
(125). 
A reaction to inflammation, infection, or trauma is a change in the 
concentration of certain plasma proteins, such as fibrinogen, haptoglobin, 
C-reactive protein (CRP), and serum amyloid A (127). These acute phase 
proteins are synthesized in the liver, and the process is stimulated by pro-
inflammatory cytokines, especially interleukin 1 and 6 (IL-6) as well as 
tumour necrosis factor-α (128). The purpose of the acute-phase response is 
to neutralize the “enemy” and to restore homeostasis. 
2.3.2 Chronic inflammation and C-reactive protein 
The pathogenesis of vascular complications in diabetes involves inflammation 
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and endothelial dysfunction (129-131), which are also part of the metabolic 
syndrome and of insulin resistance (129). Low-grade inflammation has itself 
been suggested to be a common ground for endothelial dysfunction and 
insulin resistance (129). Low-grade inflammation facilitates the invasion of 
monocytes into the vascular wall, which contributes to the formation of 
atherosclerosis and cardiovascular disease (132). 
CRP is a sensitive marker of inflammation and increases rapidly in 
response to several disease conditions. The generally held clinical cutoff for 
significant inflammatory disease is 10.0 mg/l (133), where as the introduction 
of a reproducible high sensitivity assay to measure CRP made it possible 
to obtain further information from values between 3-10 mg/l and even 
below 3 mg/l (134). The median value in healthy people, after exclusion of 
smokers and users of oral contraceptives, is between 0.6 and 1.7 mg/l. The 
median increases to 2.2 in men and to 2.4 in women among smokers and if 
contraceptives are used. The upper end (97.5th percentile) of the reference 
interval is between 3 and 6 mg/l (134-137). 
In prospective studies, high concentrations of CRP have been associated 
with increased risk for coronary heart disease and myocardial infarction (MI) 
(138-145). Interestingly, even CRP concentrations below 1 mg/l have been 
associated with increased risk for MI, coronary heart disease mortality, and 
ischemic stroke (140-142, 146). 
2.3.3 Determinants of C-reactive protein
The degree of adiposity is a major determinant of CRP in the general 
population (147-149). Waist circumference is also an important determinant 
and source of variation in the CRP concentrations (149). A weight loss 
program which includes a Mediterranean diet and moderate physical activity 
proved to have a favorable effect on CRP, proinflammatory cytokines, and 
endothelial function in obese premenopausal women (150, 151). Weight 
loss achieved by a caloric restriction diet alone also decreased CRP in obese 
postmenopausal women (152). 
The role of physical activity in CRPlevels remains unclear, since regular 
physical activity is also generally associated with a lower degree of body 
fat. Regular and nearly daily vigorous physical activity was associated with 
reduced risk for elevated CRP when compared to sedentary individuals in 
the NHANES study (153, 154). Cardiorespiratory fitness, measured with the 
maximal treadmill test, was associated with lower CRP concentrations in 
men and women (155, 156). In the Physicians Health Study, however, physical 
activity showed no association with CRP after adjustment for BMI (157).
Smoking was associated with high CRP when smokers were compared to 
those who had never smoked, and based on the fact that former smokers 
are at lower risk for high CRP than are current smokers. This association 
represents further evidence of the benefit of stopping smoking (158).
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Pharmacologic interventions also affect serum CRP concentrations. Both 
statin treatment and antihypertensive medication with ACE inhibitors were 
associated with decreased serum CRP (159, 160). 
2.3.4 Chronic inflammation and diabetic nephropathy 
In patients with diabetic nephropathy and those with incipient nephropathy 
(microalbuminuria), studies have reported increased CRP concentrations, 
suggesting that inflammation may play a role in the process of failing 
kidney function (161-163). However, these studies did not measure IL-6, 
a proinflammatory cytokine produced by many cells such as adipocytes, 
activated leucocytes, myocytes and endothelial cells (145, 164-167). The 
measurement of IL-6 is crucial, since studies show it is the main stimulus 
for the hepatic production of CRP (168, 169), and that its gene transcripts 
are expressed in human atheromatous lesions (170). Expression studies 
have further shown that IL-6 mRNA is present in the mesangium of renal 
specimens from diabetic subjects (171). Interestingly, CRP itself has been 
shown to stimulate monocyte release of IL-6 (164).
The role of chronic inflammation in patients with type 1 diabetes and 
diabetic nephropathy obviously remains somewhat unclear as available 
studies have shown rather contradictory results (161, 172). Myrup et al. 
failed to detect any increase in CRP in patients with type 1 diabetes, even in 
the macroalbuminuria stage, when compared to healthy controls. However, 
IL-6 was elevated in those patients with diabetes, and diabetic patients with 
normoalbuminuria already differed from healthy controls (172). In contrast, 
Schalkwijk et al. observed an association between CRP and DN, and even 
patients with normoalbuminuria had higher CRP than did healthy control 
subjects (161). They presented no data on IL-6, however, and given the close 
relationship between IL-6 as the stimulus and CRP as the product, showing 
a simultaneous increase in both markers as a proof of the presence of 
inflammation is important.
Declining renal function has been associated with increased serum 
cytokine levels, such as those of IL-6, IL-8, and TNF-α (173). Possible causes of 
chronic inflammation in chronic kidney disease in patients with diabetes are 
most likely multifactorial (174, 175). It is noteworthy that AGEs and oxidative 
stress are enhanced in chronic kidney disease, and that both presumably 
play a role in the activation of mononuclear cells and in the inflammatory 
response (176, 177). Diabetes is in itself a state of chronic hyperglycemia 
associated with oxidative stress and presents from the onset of disease (178). 
One can thus hypothesize that in diabetes, not only diabetes per se, but 
also its consequences (advanced glycation end-products and oxidative stress) 
promote chronic inflammation in susceptible individuals. 
Increased concentrations of IL-6 and CRP have been observed in patients 
with type 2 diabetes, a finding that suggests the presence of chronic low-
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grade inflammation. High IL-6 and CRP concentrations have even been 
shown to predict the development of type 2 diabetes (179). Furthermore, 
IL-6 is associated with visceral obesity and insulin resistance, both of which 
are key features of microalbuminuria and macrovascular complications in 
patients with type 2 diabetes (180). Figure 1 shows known associations 
between low-grade inflammation, insulin resistance, atherosclerosis, and 
diabetic nephropathy. Interestingly, in patients with type 1 diabetes, insulin 
resistance has also been shown to play a central role in the pathogenesis of 
diabetic nephropathy (181).
FIGURE 1. Chronic inflammation and its associations with insulin resistance, 
atherosclerosis and diabetic nephropathy (+ = an association shown). AMI, acute 
myocardial infarction; CRP, C-reactive protein; IL-6, interleukin-6; T1 DM, type 1 
diabetes; T2 DM, type 2 diabetes
Although evidence suggests that low-grade inflammation may be 
associated with diabetic nephropathy, whether this is a true relationship 
remains unknown. Furthermore, whether chronic inflammation is associated 
with renal function, blood pressure, waist-to-hip ratio, and insulin resistance 
in patients with type 1 diabetes also remains unknown.
2.4 The complement system
2.4.1 The complement system and lectin pathway
The complement system can be activated by three different pathways 
(Figure 2) of which the lectin pathway most probably predates the classical 
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FIGURE 1. Chronic inflammation and its associations with insulin resistance, atherosclerosis and 
diabetic nephropathy (+ = an association shown). AMI, acute myocardial infarction; CRP, C-reactive 
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FIGURE 2. Complement activation pathways (Modified from ref. 185). Ab, antibody; 
C1qrs, a multi-subunit complement factor (C1q, C1r, and C1s); C2, C3 and C4, 
complement  factors 2, 3, and 4; MBL, mannan-binding lectin; MASP2, MBL-associated 
serine protease 2
Mannan-binding lectin (MBL), a key molecule of the innate immune 
system, is synthesized by the liver and secreted into the bloodstream 
(183). MBL belongs to the C-type lectins and features binding sites for 
carbohydrates. MBL can bind to common carbohydrate structures such 
as mannose and N-acetylglucosamine (184, 185). If carbohydrates are 
present in the correct pattern (e.g. on the surface of micro-organisms), the 
binding of MBL will result in direct opsonophagocytosis and activation of 
the complement by MBL-associated proteases via the lectin pathway (183, 
185-187).
The median serum MBL concentration is 800 to 1000 µg/l in healthy 
Caucasians (188, 189), but it is worth noting that serum concentration varies 
considerably in humans. This variability is due largely to genetic diversity (i.e. 
polymorphisms that lead to amino acid replacements in the collagen-like 
region of the MBL). These polymorphisms in the coding region will affect 
MBL assembly and stability, but the final MBL is also under the influence 
of polymorphisms in the promoter region (190). Interestingly, a low level 
of MBL negatively affects the outcome of infectious diseases, which was 
observed in very young children with acute respiratory tract infections and 
in patients with severe infections after chemotherapy (191, 192). Patients 
with cystic fibrosis and low MBL concentrations have even been shown to 
have a shortened life expectancy (193).
A high level of MBL, however, in spite of offering protection against 
invading organisms, may also be deleterious to the host in some disease 
states through exaggerated complement activation (194, 195). Thus, a 
high MBL was associated with the aggravation of ischemic injury in an 
animal model of an acute myocardial infarction (MI) (196). In humans, 
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MBL has been suggested as the main mediator of complement activation 
during thoraco-abdominal aortic aneurysm repair, an operation of extensive 
ischemia reperfusion and systemic inflammation (197).
2.4.2 The complement system and diabetic nephropathy 
As previously highlighted, diabetic nephropathy may be associated with 
low-grade inflammation, and activation of the complement system may 
contribute to this inflammatory process (198). Patients with type 1 diabetes 
and normal AER show higher levels of MBL than do healthy subjects. 
Although the MBL concentration was associated with AER, no correlation 
was observed evident between MBL and CRP in these patients (198). On the 
other hand, patients with type 1 diabetes and diabetic nephropathy seem 
to have even higher levels of MBL than do patients with normoalbuminuria. 
A history of cardiovascular disease was associated with high MBL in these 
patients (199). Although patients with diabetic nephropathy have higher 
CRP concentrations than do patients with an AER in the normoalbuminuric 
range, no association was observed between MBL and CRP in this patient 
population (199). 
Reasons for the differences in MBL concentrations between patients with 
diabetes and healthy controls remains unknown. Genetic differences failed 
to explain the higher MBL concentrations in patients with type 1 diabetes, 
however (199, 200). One possible explanation could be that hypoinsulinemia 
in the portal vein upregulates MBL expression in the liver in patients with 
subcutaneous insulin injections (199). In patients with diabetic nephropathy, 
high-expression MBL genotypes were more prevalent and could in part 
explain why these patients showed higher MBL concentrations than did 
patients without nephropathy (199). 
The mechanism behind the potentially deleterious effect of high MBL in 
patients with diabetic nephropathy is also unknown. In other chronic renal 
diseases, such as IgA nephropathy and Henoch-Schönlein purpura nephritis, 
upregulation of MBL and activation of the complement system have been 
implicated in the disease process (201, 202). The IgA molecule is a heavily 
glycosylated molecule with mannose-type N-linked glycan chains that can 
be recognized and bound by MBL (185).
In patients with type 1 diabetes, chronic hyperglycemia and an 
abundance of AGEs are typical features that have been suggested to alter 
the autoreactivity of MBL (199). However, thus far remains unknown, 
whether MBL increases in parallel with the severity of diabetic nephropathy.
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2.5 Adiponectin
2.5.1 Adiponectin 
Adiponectin, a hormone with a Mr of 30000 is structurally similar to 
complement factor C1q (203). Adiponectin is secreted exclusively from 
adipocytes and, compared to many other important hormones, is abundantly 
released into circulation (203, 204),. Adiponectin accounts for up to 0.05% 
of total serum protein (203), and several isoforms have been characterised 
(205, 206). The ability of adiponectin to polymerize, resulting in trimers and 
higher-order polymers, is suggested to be crucial for its biological activity 
(205, 206). The collagenous domain of the molecule has four conserved 
lysines that can be hydroxylated and glycosylated, both of which are 
processes proposed to be critical for the three-dimensional structure of the 
biologically active adiponectin molecule (207). In fact, glycosylation likely 
represents one of the major posttranslational modifications of adiponectin 
(207).
FIGURE 3.  Adiponectin: Regulation, target, and action (Modified from Ref. 209). HGP = 
hepatic glucose output, FAOx = fatty acid oxidation, TG cont = triglyceride content
Adiponectin is a hormone that plays a role in the regulation of glucose 
and lipid metabolism (Figure 3) (208, 209). Two cell-surface adiponectin 
receptors have been characterized and cloned, and the liver and the muscle 
show the most prominent expression (210). The binding of adiponectin to 
its receptor leads to the stimulation of adenosine monophosphate (AMP)-
activated protein kinase and the activation of peroxisome proliferator-
activated receptor-α, which in turn positively affects glucose uptake and 
fatty acid oxidation in the muscle as well as the reduction of molecules 
involved in hepatic gluconeogenesis (207, 211). The activation of AMP kinase 
has also been linked to proliferator-activated receptor-γ co-activator-1, and 
thus to mitochondrial oxidation and glucose uptake (212). 
Adiponectin has also been shown to exert anti-atherosclerotic effects 
by inhibiting neointimal thickening and vascular smooth muscle cell 
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FIGURE 3.  Adiponectin: Regulation, target, and action (Modified from Ref. 209). 
HGP = hepatic glucose output, FAOx = fatty acid oxidation, TG cont = triglyceride content                 
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In contrast to observed increases in the plasma levels of several adipokines 
(leptin, resistin), the plasma levels of adiponectin are markedly reduced 
in individuals with visceral adiposity (Figure 4). Low plasma adiponectin 
concentrations thus occurs in obesity (204, 215) and type 2 diabetes (215, 
216), but also in patients with coronary artery disease (216, 217). 
Figure 4. Adipose tissue as an endocrine organ: many functions and products. IL-6, 
interleukin-6; NEFA, non-esterified fatty acid; PAI-1, plasminogen-activator-inhibitor-1; 
TNF-α and -β, tumor necrosis factor-α and -β
Circulating levels of adiponectin thus negatively correlate with insulin 
resistance, fasting serum insulin, serum triglycerides, and fasting plasma 
glucose concentrations (216, 218-220). 
Adiponectin is also generally lower in males than in females (215, 219), 
a gender difference attributed to the effect of testosterone (221). 
Importantly, high basal plasma adiponectin levels were associated 
with a reduced risk for MI in men in a nested case-control study with a 
follow-up of six years (222). 
Besides its anti-atherosclerotic effect, adiponectin also has an 
anti-inflammatory effect. Thus, in the early stage of atherosclerosis, 
physiological concentrations of adiponectin have been shown to inhibit 
tumor necrosis factor (TNF)-α-induced monocyte adhesion and the 
expression of adhesion molecules in vascular endothelial cells (217). 
Adiponectin furthermore negatively correlates with CRP in patients 
with coronary atherosclerosis (223), and both plasma IL-6 and CRP 
concentrations appear inversely associated with adiponectin in obese 
women (224). IL-6 has also been shown to downregulate adiponectin gene 
expression in adipocytes (225).
Weight reduction increases adiponectin not only in patients with 
diabetes, but also in non-diabetic subjects (216). Interestingly, the insulin 
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Figure 4. Adipose tissue as an endocrine organ: many functions and products. IL-6, interleukin-6;  
NEFA, non-esterified fatty acid; PAI-1, plasminogen-activator-inhibitor-1; TNF-α and -β, tumor 
necrosis factor-α and -β 
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insulin sensitivity in patients with type 2 diabetes and stimulate the 
synthesis of adiponectin (226, 227).
2.5.2 Adiponectin in patients with type 1 diabetes and   
 diabetic nephropathy
Adiponectin concentrations are higher in patients with short duration of 
type 1 diabetes than in weight-matched healthy volunteers, observation also 
replicated in patients with a long duration of type 1 diabetes and normal 
kidney function (228-230). The reason for this finding remains unknown, 
although some have speculated that this finding may be related to the 
glycosylation of the adiponectin molecule (207). 
Notably, adiponectin concentrations have consistently proved higher in 
patients with renal disease than in healthy control subjects, even if the same 
patients also display insulin resistance and increased risk for cardiovascular 
disease (231, 232). In patients with advanced ESRD, high adiponectin 
concentrations were associated with type 1 diabetes, low visceral fat mass 
and low CRP (231). However, these studies included only a small number of 
patients with type 1 diabetes, and thus, the rather unexpected finding of 
high adiponectin concentrations when one would expect low concentrations 
must be replicated in larger patient cohorts. 
The mechanism responsible for the increase of adiponectin consistently 
observed in ESRD remains unclear. Because high plasma adiponectin 
concentrations decrease after renal transplantation, renal insufficiency may 
either affect the clearance of adiponectin or stimulate its production or 
both (233).
A number of questions still await answers. For instance, whether 
adiponectin increases in parallel with the severity of diabetic nephropathy 
or whether adiponectin is associated with inflammation and metabolic 
control in patients with type 1 diabetes at various stages of renal function 
remains unknown. Furthermore, whether baseline adiponectin predicts the 
progression of diabetic nephropathy also remains unknown. 
2.6 Defensins 
2.6.1 The defensin family
Defensins belong to an antimicrobial peptide family, consisting of 
polypeptides with fewer than 100 amino acids. They function as a part of the 
innate local host response of multicellular organisms. Antimicrobial peptides 
have been found in both non-vertebrates, such as plants and insects, and 
vertebrates ranging from amphibians to humans, which suggests that these 
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defense molecules predate the evolutionary divergence of animals and 
plants (123, 234-237). 
The defensin family itself consists of small cystein-rich peptides, 30 to 40 
aminoacids in mammalians, with broad cytotoxic activity against bacteria, 
fungi, parasites, viruses, and host cells (123, 237, 238). Mammalian defensins 
are further organised into three classes: α-, β- and θ-defensins (238). 
The role of the defensin family in the human innate immune system 
is based on studies of α- and β-defensins, since the peptide production of 
known human θ-defensin genes remains to be shown (239). 
2.6.2 α-defensins
Human α-defensins, a group of six peptides, are predominantly found in 
neutrophils and in intestinal Paneth cells (237-239). Neutrophil-originated 
α-defensins, α-defensins-1 to -4, are also called human neutrophil peptides 
(HNP). These defensins are synthesized constitutively in the bone marrow 
during specific differentiation stages of neutrophil development in 
promyelocytes and early myelocytes. They are stored in the granules of 
phagocytes and released on demand from these cytoplasmic granules (237, 
240, 241). The first three (α-defensin-1, -2 and -3) have a similar structure, 
with a difference of only one amino acid between each other (FIGURE 5) 
(123, 237).
FIGURE 5. The amino acid structure of α-defensin-1, -2, and -3 (Mod. from Ref 123)
It is worth noting that even if the production of α-defensin has not yet 
been shown to be inducible by inflammatory mediators, such as β-defensin-2 
and -3 (242), the expression of α-defensin in the neutrophils can be increased 
by granulocyte colony-stimulating factor (GC-SF) (243).
α-defensins are involved in the intracellular destruction of foreign 
pathogens but can also be released into the extracellular environment by 
neutrophil degranulation and thereby contribute to the innate host defence 
against microbial invasion (243). In addition, α-defensins-1 to -3 have been 
observed to be chemotactic for monocytes and naïve T cells (244, 245). 
Based on in vitro studies, however, human defensins have also been 
suggested to have a deleterious effect on host cells (242). In addition, 
                                          α-defensin-1     
                   ACYCRIPACIAGERRYGTCIYQGRLWAFCC 
 
                                           α-defensin-2         
                      CYCRIPACIAGERRYGTCIYQGRLWAFCC
 
                                          α-defensin-3   
                   DCYCRIPACIAGERRYGTCIYQGRLWAFCC
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some defensins have been shown to be cytotoxic to mammalian cells in 
higher concentrations (245-248). High concentrations of defensins are 
associated with the generation of pro-inflammatory signals (249), which is 
a phenomenon suggested to contribute to tissue injury in the lungs (250).
Plasma and serum α-defensin levels may decrease with activated alpha2–
macroglobulin, a protease inhibitor able to bind to defensin peptides (251). 
It is noteworthy that patients with diabetes have higher serum alpha2-
macroglobulin levels than do healthy controls (252). Whether interaction 
between these molecules plays a physiological role remains unknown. 
α-defensins, shown to inhibit or to enhance inflammation in many 
ways, can stimulate the cytokine production of bronchial epithelial cells 
and modify inflammation through regulation of cytokine production in 
human monocytes and adhesion molecule expression in endothelial cells 
(249, 253). Regarding interference with complement system, α-defensin 
has been shown to either stimulate or suppress activation of the classical 
complement pathway (254, 255). In addition, α-defensin can reportedly 
inhibit the fibrinolytic system and to stimulate the binding of lipoprotein 
(a) and low-density lipoprotein to vascular cells. Thus, α-defensin may be a 
true link between inflammation and atherosclerosis (256-258). 
2.6.2 α-defensin and diabetic nephropathy
Defensins, as a part of the innate immune system, appear to play a role in 
the regulation of the complement system and to augment the production 
of pro-inflammatory cytokines (240, 259). 
Whether α-defensin is also associated with diabetic nephropathy and 
with low-grade inflammation and blood lipid values in patients with 
nephropathy remains unknown.
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3. Aims Of The Study 
One-third of patients with type 1 diabetes still develop diabetic nephropathy despite 
modern treatment options, and diabetic nephropathy is the most important cause 
of renal failure in the industrialized world. Because diabetic nephropathy and 
macrovascular disease are strongly associated, some have suggested that micro-and 
macrovascular complications may share a common origin, such as inflammation and 
a generally over-active innate immune system. The present studies were therefore 
undertaken to explore the possible role of inflammation, mannan-binding lectin, 
adiponectin, and defensin as a part of the deleterious process of diabetic nephropathy 
in patients with type 1 diabetes.
The main objectives were to answer the following questions:
1. Is low-grade inflammation associated with diabetic nephropathy in patients with 
type 1 diabetes? (I)
2. Is mannan-binding lectin (MBL) associated with diabetic nephropathy in patients 
with type 1 diabetes, and is there an association between MBL and low-grade 
inflammatory markers or insulin resistance? (II)
3. Is serum adiponectin associated with renal function, low-grade inflammatory 
markers, metabolic control, and insulin resistance in patients with type 1 diabetes? 
(III)
4. Is α-defensin (-1, -2, and -3) associated with renal function, low-grade inflammatory 
markers, and the blood lipid profile of patients with type 1 diabetes? (IV)
5. Does adiponectin play a role in the development and progression of diabetic 
nephropathy in patients with type 1 diabetes? (V)
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4. Subjects
4.1 Cross-sectional studies (I-IV)
This study was part of the ongoing Finnish Diabetic Nephropathy Study 
(FinnDiane). The first four substudies (I-IV) were cross-sectional, and the last 
(V) was a follow-up study. The studies were conducted in accordance with 
the Declaration of Helsinki, and the ethical committees of all participating 
centers approved the study protocol. Each subject provided his or her 
written informed consent.
To mimimize the effect of potential confounding factors, we carefully 
selected patients in order to achieve representative phenotypes of patients 
with normo- , micro-, or macroalbuminuria. Patients for the cross-sectional 
studies (I-IV) were selected from the entire study population of 1616 patients 
with complete information available about their histories of hypertension, 
diabetes, cardiovascular disease and the mortality of both of their parents. 
The patients were required to have a duration of diabetes of 10 to 30 years, 
which reduced the number of eligible patients to 882. To assure renal status, 
three complete urine collections were required, which reduced the number 
of eligible patients to 577. Those patients with normal AER were further 
required to take neither antihypertensive medication nor show any signs 
of cardiovascular disease, whereas those patients with microalbuminuria or 
macroalbuminuria were required to be undergoing ACE inhibitor treatment. 
In all substudies, the patients were divided into three groups (normo-, 
micro-, or macroalbuminuria) according to their AER in three consecutive 
overnight or 24-h urine collections. Normal AER (normoalbuminuria) was 
defined as an AER persistently < 20 µg/min or < 30 mg/24 h, microalbuminuria 
as AER ≥ 20 < 200 µg/min or ≥ 30 < 300 mg/24 h, and macroalbuminuria as 
AER ≥ 200 µg/min or ≥ 300 mg/24 h in at least two of three urine collections. 
Type 1 diabetes was defined as the onset of diabetes before the age of 35 
years and the initiation of permanent insulin treatment within one year of 
diagnosis.
A total of 401 patients with type 1 diabetes met all these selection 
criteria. Thereafter, the patient groups were matched for duration of 
diabetes. Because the shortest disease duration in the macroalbuminuric 
group was 13 years, this cut-off point was chosen for all patients. Finally, the 
patients were matched for sex, which resulted in 194 patients representive 
of a wide range of AER. At inclusion, five microalbuminuric and eight 
macroalbuminuric patients were treated with statins. None of the patients 
used acetosalicylic acid.
In study I, 194 patients were divided into three groups based upon their 
AER. Patients with normoalbuminuria (n = 67) received no antihypertensive 
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medication or showed no signs of cardiovascular disease, whereas all patients 
with microalbuminuria (n = 64) or macroalbuminuria (n = 63) were treated 
with an ACE inhibitor. A total of 66 healthy volunteers comprising Finnish 
research scientists and laboratory personnel working at the Folkhälsan 
Research Center in Biomedicum Helsinki served as a control group. 
Study II included a total of 191 patients, which was three less than in the 
first study. This was due to the fact that insufficient serum remained for the 
analyses in two patients in the microalbuminuria group and in one patient 
in the macroalbuminuria group.
Studies III and IV comprised a total of 189 patients, two less than in the 
second study for the same reason: due to a lack of serum samples for two 
patients with microalbuminuria. 
4.2 Follow-up study (V)
In the prospective follow-up study (V), the main outcome was the 
progression of albuminuria. At baseline, all patients participating in the 
FinnDiane Study underwent a thorough clinical investigation that took place 
in conjunction with a regular visit to the attending physician. The medical 
file of every patient included in the analysis was reviewed, and any changes 
in renal status or the occurrence of cardiovascular events was verified. All 
the patients were re-examined at their local medical center according to the 
same protocol used during the baseline visit. Based on these procedures, 
1330 type 1 diabetic patients were included in the study with a mean 
follow-up of 5.0 ± 2.2 years. Patients were divided at baseline into three 
groups according to their AER: 818 patients with normoalbuminuria, 216 
patients with microalbuminuria, and 296 patients with macroalbuminuria. A 
total of 204 non-related healthy control subjects of Finnish origin, recruited 
from the personnel of Biomedicum Helsinki and their spouses (108 female 
and 96 male), with a mean age of 36.1 years and a BMI of 23.9 kg/m2, were 
also included to compare adiponectin concentrations between healthy 
subjects and patients with type 1 diabetes. 
4.3 Study design
In the first cross-sectional study, low-grade inflammatory markers IL-6 and 
CRP were measured and correlated with AER and estimated GFR (eGFR). 
Furthermore, we assessed a possible association of low-grade inflammation 
with clinical variables and the estimated glucose disposal rate (eGDR) [as a 
measure of insulin sensitivity]. 
In the second study, MBL was measured and correlated with AER and 
eGFR. In addition, we assessed a possible association of MBL with low-grade 
inflammatory markers and eGDR. 
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In the third study, adiponectin was measured and correlated to AER and 
eGFR. Furthermore, we assessed a possible association of adiponectin with 
low-grade inflammatory markers, eGDR, and clinical variables/metabolic 
control. 
In the fourth cross-sectional study α-defensin (-1, -2, and -3) was 
measured and correlated with AER and renal function. Furthermore, we 
assessed a possible association of α-defensin (-1, -2, and -3) with low-grade 
inflammatory markers, serum lipids, and clinical variables. 
In the fifth study, the follow-up study, the main outcome was the 
progression of diabetic nephropathy, a change in the albumin excretion 
rate from one level to a higher level (normo- → microalbuminuria or 
micro- → macroalbuminuria) or the development of ESRD. Adiponectin 
was measured at baseline and correlated with the progression of diabetic 
nephropathy during the follow-up of the entire study population as well 




In the cross-sectional studies (I-IV), data on medication, smoking, 
cardiovascular status, diabetic complications, and parental history of 
diabetes, hypertension, and cardiovascular disease were registered with a 
standardized questionnaire completed by the patient’s attending physician 
based upon medical files. 
In the follow-up study (V), two different approaches complementing each 
other were used. First, the medical files were reviewed, and any changes in 
renal status or the occurrence of cardiovascular events was verified. Second, 
patients were re-examined at their local medical center according to the 
same protocol as during the baseline visit. 
5.2 Blood pressure and demographics
Blood pressure was measured twice in the sitting position with a 
mercury sphygmomanometer after a 10-min rest. The mean of these two 
measurements served in the analyses. Height, weight, as well as waist and 
hip circumferences were recorded, and the body-mass index (BMI=weight 
[kg]/height2 [m2]) and the waist-to-hip ratio (WHR) was calculated. 
5.3.1 Albumin excretion rate and renal function 
Urine samples were collected in one of two ways: by a timed overnight or 
24-h urine collection. Urinary AER was determined by radioimmunoassay 
until November 2002 (Pharmacia, Uppsala, Sweden), and thereafter by 
immunoturbidimetry with a correlation coefficient of 0.96 between these 
two methods. The patients were divided into three groups according to 
their AER in three consecutive overnight or 24-h urine collections. Normal 
AER (normoalbuminuria) was defined as an AER persistently < 20 µg/min 
or < 30 mg/24 h, microalbuminuria as AER ≤ 20 < 200 µg/min or ≤ 30 < 
300 mg/24h, and macroalbuminuria as AER ≥ 200 µg/min or ≥ 300 mg/24 h 
in at least two of three urine collections. Serum creatinine was assessed with 
enzymatic methods at a central laboratory. To determine renal function, we 
estimated GFR with an equation derived from the Modification of Diet in 
Renal Disease (MDRD) Study (260, 261) as well as with the Cockroft-Gault 
formula (262). 
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5.3.2 Definition of progression of diabetic nephropathy 
 (Study V)
All data on AER obtained between baseline and the follow-up visit were 
reviewed and based on the result in two of the last three consecutive urine 
collections, the renal status of the patients was determined using the same 
cut-off values as in the baseline examination. Progression was defined as 
a change from one level to a higher level of AER or the development of 
ESRD. Patients with no progression of renal disease were classified as non-
progressors.
5.4 Glucose control, lipids, and insulin sensitivity 
HbA1c was determined locally by standardized assays at each center. Serum 
lipid and lipoprotein concentrations were measured centrally at the research 
laboratory of the Helsinki University Central Hospital, Division of Cardiology, 
Helsinki, Finland, with automated enzymatic methods that use the Cobas 
Mira analyzer (HoffmanLa Roche, Basel, Switzerland). As a measure of 
insulin sensitivity, we calculated the estimated glucose disposal rate (eGDR) 
with an equation modified for HbA1c, as previously described (263).
5.5 Low-grade inflammatory markers CRP and IL-6
CRP was measured with radioimmunoassay; CRP standards (Orion 
Diagnostica, Espoo, Finland) and patients’ sera were incubated with sheep 
CRP antiserum (Code C 4063, Sigma Chemical Co, St. Louis, Mo., USA) and 
with Sepharose anti-sheep IgG (Pharmacia, Uppsala, Sweden) for 1 h at 
room temperature, and were then centrifugated. The radioactivity of the 
pellets was measured, and the standard curve was used for the calculations 
(264). Within- and between-assay CVs were, respectively, 4.0% and 6.5%. 
The detection limit of the assay was 0.01 mg/l. 
IL-6 was determined with a quantitative sandwich enzyme immunoassay 
technique, that used a monoclonal and an enzyme-linked polyclonal 
antibody specific for IL-6 (Quantikine HS human IL-6 immunoassay, R&D 
Systems, Minneapolis, MN, USA). Within- and between-assay CVs were, 
respectively 2.6% and 4.5%. The detection limit for IL-6 was 0.1 ng/l. 
CRP and IL-6 were also measured in sera from 66 healthy control subjects 
(36 women and 30 men with a mean age of 37.6 years [range 19–63]). In 
these control subjects, the concentration of CRP varied from 0.2 to 4.8 mg/l 
(means ± SD; 1.2 ± 1.0 mg/l), and the IL-6 concentration varied from 0.13 to 
5.20 ng/l (1.25 ± 1.07 ng/l) (264).
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5.6 Mannan-binding lectin (MBL) 
Serum MBL concentrations were determined with an in-house time-
resolved immunofluorometric assay at the University of Aarhus, Denmark. 
The measurement was based on monoclonal antibody (anti-MBL-antibody, 
Immunolex, Denmark, labeled with reagents from Perkin Elmer, USA). 
The intra- and interassay CVs were below 5% and 10%, respectively. The 
detection limit for MBL was 10 ng/ml (265). 
5.7 Adiponectin 
Serum adiponectin was determined with an in-house time-resolved 
immunofluorometric assay at the University of Aarhus, Denmark. The 
measurement was based on two monoclonal antibodies and recombinant 
human adiponectin (R&D Systems, Abingdon, UK). The within-assay CVs of 
standards and unknown samples averaged less than 5%. The between-assay 
CV was 12% at a final dilution of 1:2500 and 8% at a final dilution of 1:50 
(266). The detection limit for adiponectin was less than 1.5 mg/l. 
5.8 a-defensin 
The plasma level of a-defensin was determined with a novel, validated, 
in-house, solid-phase radioimmunoassay (RIA) technique at the University 
of Aarhus, Denmark. The measument was based on a monoclonal antibody, 
which recognizes a-defensin isoforms 1-3. The mean within-assay CVs of 
standards and samples was less than 6%. The in-between assay CV was 9% 
(267). The detection limit of a-defensin was less than 1.95 µg/l.
5.9 Statistical analysis
Data are expressed as means ± SD for normally distributed values, as median with 
a range for non-normally distributed values, and as percentages. Differences 
between groups for normally distributed variables were tested using ANOVA 
and non-parametric data with the Mann-Whitney or Kruskal-Wallis tests. 
Frequencies were tested with Pearson’s Chi-squared test or two-tailed Fisher’s 
exact test when appropriate. Correlations were calculated using simple and 
multiple linear regression analysis. In study V, risk factors for the progression of 
diabetic nephropathy were assessed using Cox regression analysis. Calculations 
in studies I-III were carried out with a BMDP statistical package (BMDP Statistical 
Software, Los Angeles, CA, USA). In studies IV and V calculations were performed 
with SPSS 12.01 software (SPSS Inc., Chicago, Illinois, USA). In all studies, a P value 
of less than 0.05 was considered statistically significant.
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6. Results 
6.1 Inflammatory markers at various stages of diabetic 
nephropathy (I) 
The concentrations of serum low-grade inflammatory markers, C-reactive 
protein (CRP), and interleukin-6 (IL-6) appear in Figure 6.
Figure 6. CRP and IL-6 concentrations in 194 Type 1 diabetic patients with and 
without diabetic nephropathy, as well as in 66 healthy control subjects. NORMO, 
normoalbuminuria; MICRO, microalbuminuria, MACRO, macroalbuminuria. Data are 
medians.
CRP was higher in patients with incipient (microalbuminuria) and overt 
(macroalbuminuria) diabetic nephropathy than in normoalbuminuric 
patients, whereas interleukin-6 increased in parallel with the severity of the 
renal disease. No difference was observed in CRP concentrations between 
the micro- or macroalbuminuria groups of patients. Healthy controls had 
lower CRP and IL-6 than did patients with diabetes, either with or without 
diabetic nephropathy. 
Il-6 and CRP correlated positively with each other (r = 0.3291, P < 0.0001). 
In the univariate analysis, CRP correlated positively with diastolic blood 
pressure, as did triglycerides and AER; CRP and eGDR showed a negative 
correlation. IL-6 correlated positively with the duration of diabetes, WHR, 
HbA1c, creatinine, triglycerides, and AER, and inversely with eGDR, HDL-
cholesterol, and eGFR (MDRD). 
In a multiple linear regression analysis with diastolic blood pressure, 
eGDR, triglycerides, and AER in the model, an independent relationship 
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Figure 6.  CRP and IL-6 concentrations in 194 Type 1 diabetic patients with and 
without diabetic nephropathy, as well as in 66 healthy control subjects. NORMO, 
normoalbuminuria; MICRO, microalbuminuria, ACRO, macroalbuminuria. Data  
are medians.
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IL-6 was independently associated with the duration of diabetes (0.03 ± 0.1, 
P = 0.0176), HDL-cholesterol (-0.29 ± 0.12, P = 0.0135), and AER (0.10 ± 0.03, 
P = 0.0003) in a model that also included WHR, eGDR, HbA1c, creatinine, 
eGFR, and triglycerides. 
6.2 MBL at various stages of diabetic nephropathy (II) 
The MBL concentrations appear in Figure  7. MBL was higher in 
microalbuminuric patients than in normoalbuminuric patients, but as 
with CRP, no difference was observed in the MBL concentrations between 
patients with microalbuminuria and those with macroalbuminuria.
Figure 7.  MBL levels (median with interquartile range) in 191 type 1 diabetic patients 
with and without diabetic nephropathy. NORMO = normoalbuminuria, MICRO = 
microalbuminuria, MACRO = macroalbuminuria. 
MBL correlated with HbA1c, HDL-cholesterol, and eGDR. However, no 
significant correlations were observed between MBL and inflammatory 
markers CRP or IL-6 or between any of the other variables tested. 
In a multiple regression analysis with HbA1c, eGDR, and HDL-cholesterol 
in the model, HbA1c was the only variable independently associated with 
MBL (β ± SEM: 0.26 ± 0.08; P = 0.003).
6.3 Adiponectin in patients with type 1 diabetes (III) 
Adiponectin concentrations were clearly higher in females than in males, 
but because no significant differences in gender distribution between the 
groups were observed, the data were pooled in the analyses. Adiponectin 
concentrations were higher in patients with macroalbuminuria (19.8 
± 12.0 mg/l) than in patients with microalbuminuria (13.1 ± 4.8 mg/l) or 
normoalbuminuria (11.8 ± 4.2 mg/l). However, no difference was observed 

















Figure 7.  MBL levels (median with interquartile range) in 191 type 1 diabetic patients with and without diabetic 
nephropathy. NORMO = normoalbuminuria, MICRO = microalbuminuria, MACRO = macroalbuminuria.  
P=0.029 P=NS
P=0.019
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Figure 8. Adiponectin concentration (mg/l) in all (n = 189) type 1 diabetic patients. 
Data are means ± SD. NORMO = normoalbuminuria (n=66), MICRO = microalbuminuria 
(63), and MACRO = macroalbuminuria (n=60).
In univariate analysis, adiponectin was positively associated with 
creatinine, AER, interleukin-6, systolic blood pressure, HbA1c, total 
cholesterol, and HDL-cholesterol, and inversely with eGFR and WHR.
In a multiple linear regression analysis, including the above mentioned 
variables, eGFR (β ± SE: -0.47 ± 0.10; P < 0.0001), AER (0.07 ± 0.02; P < 
0.0001), and WHR (-1.30 ± 0.38; P < 0.001) were independently associated 
with serum adiponectin concentrations (R2 = 0.32).
6.4 α-defensin (-1, -2, and -3) at various stages of 
diabetic nephropathy (IV)
The total serum concentration of α-defensin (-1, -2, and -3) appears in 
Figure 9. Compared to micro- and normoalbuminuria, serum α-defensin 
concentrations were higher in diabetic patients with macroalbuminuria, 
but no difference was observed between patients with normo- and 
microalbuminuria.
Figure 9. Defensin concentration (ug/l) in type 1 diabetic patients . Data are median 




















Figure 8. Adiponectin concentration (mg/l) in all (n = 189)  type 1 diabetic patients. Data are means ± SD. NORMO = 
normoalbuminuria (n=66), MICRO = microalbuminuria (63), and MACRO = macroalbuminuria (n=60). 
P<0.0001
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Defensin  concentration (ug/l) in type 1 diabetic patients . Data are median with range. (NORMO = normoalbuminuria, 
MICRO = microalbuminuria, MACRO = macroalbuminuria) 
  P=NS 
  P<0.001 
  P<0.001 
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Since the distribution of α-defensin was not normally distributed, the 
data were logarithmically transformed before inclusion in the regression 
analyses. In univariate analysis, α-defensin correlated positively with WHR, 
systolic blood pressure and diastolic blood pressure, HbA1c, cholesterol, 
triglycerides, creatinine, AER, CRP, and IL-6, and inversely with age, age at 
onset of diabetes, HDL-cholesterol, eGDR, and eGFR. 
According to the multiple regression analysis, an independent 
relationship existed between α-defensin and age, systolic blood pressure, 
cholesterol, HDL-cholesterol, and eGFR (Table 1).
Table 1.Multiple linear regression analysis with α-defensin as the 
dependent variable.
B ± SE P-value
SBP 0.003 ± 0.001 0.032
ln(HDL-cholesterol) -0.198 ± 0.079 0.013
ln(cholesterol) 0.334 ± 0.124 0.008
Age -0.010 ± 0.003 0.001
eGFR(Cockroft-Gault) -0.264 ± 0.077 0.001
SBP = systolic blood pressure; eGFR = estimated glomerular filtration rate. Model also included 
WHR, HbA1c, lnAER, lnIL-6, lnCRP, and lnTG. R2 = 0.438. 
6.5 Adiponectin and the progression of diabetic 
nephropathy (V)
The data on adiponectin in study V, including a substantially larger number 
(n = 1330) of patients than in study III (n = 189) were similar and thus 
adequately replicated. Again, serum adiponectin concentrations were higher 
in patients with macroalbuminuria and similar in those with normo- and 
microalbuminuria (Figure 10).
 Figure 10. Serum adiponectin concentrations (mg/l) in type 1 diabetic patients. Data 
are means ± SD. NORMO = normoalbuminuria (n = 818), MICRO = microalbuminuria (n 


















Figure 10.  Serum 
adiponectin concentrations (mg/l) in type 1 diabetic patients. Data are means ± SD. NORMO = normoalbuminuria (n = 
818), MICRO = microalbuminuria (n = 216), MACRO = macroalbuminuria (n = 296).
   P=NS 
  P<0.001 
  P<0.001 
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A total of 73 (9%) of the 818 patients with normoalbuminuria 
progressed to microalbuminuria, 37 (17%) of 216 progressed from micro- 
to macroalbuminuria, and 83 (28%) of 296 from macroalbuminuria to ESRD.
In patients with normo- or microalbuminuria, no differences in the 
baseline adiponectin concentrations were observed between progressors 
and non-progressors (12.0 ± 6.1 vs. 12.1 ± 5.8 mg/l; P = NS), not even 
when analyzing men and women separately. In the macroalbuminuric 
group, however, progressors had significantly higher serum adiponectin 
concentrations than did those who did not progress (Table 2).
Table 2. Baseline adiponectin concentrations (mg/l) and the progression 
from one stage to the next in diabetic nephropathy. 
Progressor Non-progressor P-value
Macroalbuminuria (all) 23.4 ± 17.1 (83) 16.0 ± 8.5 (213) <0.001
Macroalbuminuria (men) 19.1 ± 9.9 (56) 13.5 ± 7.0 (119) <0.001
Macroalbuminuria (women) 32.2 ± 24.5 (27) 19.1 ± 9.3 (94) <0.001
Data are means ± SD (n).
In univariate analysis in patients with macroalbuminuria, a significant 
relationship emerged between progression and systolic blood pressure 
(P = 0.022), insulin dose (P = 0.001), HbA1c (P = 0.040), cholesterol (P = 0.007), 
triglycerides (P < 0.001), creatinine (P < 0.001), AER (P < 0.001), and eGFR 
(P < 0.001). 
Notably, adiponectin remained an independent predictor of progression 
from macroalbuminuria to ESRD when adjusted for the above variables in 
the Cox-regression model (Table 3)
Table 3. Cox regression analysis of risk factors for progression from 
macroalbuminuria to ESRD
 B ± SE  Hazard ratio(95% CI) P-value
eGFR 1 ml/min per1.73m2 -0.065 ± 0.008 0.937 (0.923 - 0.952) < 0.001
SBP 1 mmHg 0.009 ± 0.006 1.009 (0.997 - 1.021) 0.158
HbA1C 1 % 0.203 ± 0.076 1.225 (1.055 - 1.422) 0.008
TG 1 mmol/l 0.355 ± 0.098 1.426 (1.176 - 1.728) < 0.001
Adiponectin 1 mg/l 0.021 ± 0.008 1.022 (1.005 - 1.039) 0.011
Insulin 1 IU per kg -0.473 ± 0.681 0.623 (0.164 - 2.366) 0.487
Total cholesterol 1 mmol/l -0.110 ± 0.128 0.896 (0.697 - 1.152) 0.391
eGFR = estimated glomerular filtration rate determined with the Cockroft-Gault formula; SBP = 
systolic blood pressure;TG = triglycerides 
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7. Discussion
7.1 Subjects and methods 
7.1.1 Cross-sectional studies (I-IV)
In the cross-sectional substudies (I-IV), all patients were recruited from the 
nationwide multi-center FinnDiane study and matched for sex and duration 
of diabetes. Patients without diabetic nephropathy (normoalbuminuria) 
were required to take no antihypertensive medication, to have no signs of 
cardiovascular disease, and to have a relatively long duration of diabetes 
of at least 13 years. The cut-off of 13 years was chosen as the cut-off point 
for all patients, since that was the shortest duration for a patient in the 
macroalbuminuric group. Furthermore, long disease duration indicates that 
these patients with normoalbuminuria are at rather low risk for diabetic 
nephropathy and would thus represent true normoalbuminuric subjects. 
Patients with incipient or overt diabetic nephropathy, micro-, or 
macroalbuminuria were required to undergo treatment with an ACE 
inhibitor in order to be representative of typical patients with type 1 
diabetes and increased AER in Finland. Nearly all patients with type 1 
diabetes and with signs of incipient or macroalbuminuria in the FinnDiane 
were, at the time of the study and according to the recommendations, 
treated with an ACE inhibitor. This approach differed from those of previous 
studies, where the patients studied had either no medication, despite the 
presence of microalbuminuria, or no data were available regarding blood 
pressure medication in those patients with diabetic nephropathy (172, 161). 
This important matter is further discussed in section 7.2.1.
Low-grade inflammation was estimated by measuring both CRP and IL-6. 
CRP is an acute-phase protein produced by the liver in response to various 
stimuli, and the synthesis rate has been shown to be the only significant 
determinant of its plasma level (268). On the other hand, CRP is also a 
downstream marker of pro-inflammatory processes. It is worth noting that 
CRP has been suggested to be the “best” inflammatory marker and clinical 
tool in identifying those at risk for cardiovascular disease (145, 164), a 
complication typical for patients with diabetic nephropathy (269, 270). 
IL-6 is a proinflammatory cytokine which has been shown to be the main 
stimulus for the hepatic production of CRP (168, 169). In addition, IL-6 has 
been linked not only to atherosclerosis, but also to insulin resistance (180), 
which is also a typical feature of diabetic nephropathy, even in patients with 
type 1 diabetes (181). In clinical settings and in our studies as well, another 
strong candidate marker could have been TNF-α, but it has a short half-life 
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of less than ten minutes (271) when compared to CRP, with a half-life of 18 
hours. It is also worth noting that the CRP plasma concentrations have been 
shown to be relatively stable over several years (164).
7.1.2 Follow-up study (V) 
Two different complimentary approaches were implemented for the 
follow-up of the patients. First, their medical files were reviewed, and any 
changes in renal status or in the occurrence of any cardiovascular events 
were recorded. Second, the patients were re-examined according to the 
same protocol used during the baseline visit. 
Progression of diabetic nephropathy was defined as a change from 
one level of AER to a higher level or as the development of ESRD. Only 
those re-examined patients with available follow-up data on AER, and who 
were therefore classifiable as either progressors or non-progressors, were 
included in this follow-up study. One could argue whether the approach 
to define progression from one category to the other based on the AER 
was better or worse than using an increment of the AER (ΔAER). We chose 
this approach, however, since this is still the clinical basis for categorizing 
patients in different stages of diabetic nephropathy based on the staging 
recommendations of the ADA (272).
7.2.1 Low-grade inflammation and diabetic nephropathy in  
 patients with type 1 diabetes (I)
The concept that an inflammatory component could exist behind diabetic 
nephropathy in patients with type 1 diabetes originated from two rather 
contradictory studies. The first showed that IL-6 was already higher 
in patients with normoalbuminuria than in healthy control subjects, 
although CRP showed no differences between healthy control subjects 
and patients with type 1 diabetes at any stage of albuminuria (172). The 
second study, however, showed higher CRP concentrations in patients with 
normoalbuminuria (161). Although these two studies failed to provide a 
definite answer, they did hint that chronic inflammation may be linked to 
elevated albuminuria. 
We were able to confirm the association of low-grade inflammation 
with diabetic nephropathy in patients with type 1 diabetes and to extend 
the finding to include not only CRP, but also IL-6. Low-grade inflammation 
was already present in the early stage of microalbuminuria. The reason why 
no significant increase in CRP concentrations was observed in the previous 
study in patients with type 1 diabetes and microalbuminuria may be that 
we included a much larger patient population (273). 
We not only confirmed the previous finding that patients with type 1 
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diabetes and albuminuria have elevated CRP and IL-6 concentrations, but 
also that, CRP and IL-6 were positively correlated with each other. These 
observations are both important, since IL-6 is considered to be the main 
stimulus for the hepatic production of CRP (168, 169). 
IL-6 concentrations rose in parallel with renal engagement, and this 
difference between the groups remained evident even after adjustment 
for WHR, suggesting that low-grade inflammation is truly a part of the 
deleterious process of diabetic nephropathy, at least in patients with type 
1 diabetes. In a rather recent study in patients with type 2 diabetes, an 
increase in IL-6 was associated not only with diabetic nephropathy, but also 
with glomerular basement membrane thickening, a crucial lesion of diabetic 
nephropathy and a strong predictor of renal progression (274). 
Patients with microalbuminuria or macroalbuminuria were treated with 
an ACE inhibitor (see section 7.1.1). Since ACE inhibition has been associated 
with reduced CRP and IL-6, and is thus suggested to inhibit inflammation 
(275, 276), ACE inhibition could even have diminished the true difference 
between the groups. This further strengthens our finding and suggestion 
that diabetic nephropathy is a state of low-grade inflammation.
Duration of diabetes was independently related to IL-6 in our study, 
which suggests that chronic exposure to glucose and possibly to AGEs 
could stimulate the production of IL-6. In this respect the finding that 
serum-free pentosidine and the monocyte activation marker neopterin 
correlates with the rate of progression of diabetic nephropathy (277) 
supports our hypothesis that AGEs could activate monocytes to produce 
IL-6. Furthermore, given the fact that low-grade inflammation has been 
linked to markers of endothelial dysfunction in patients with type 1 diabetes 
and macroalbuminuria (161, 278), the source of IL-6 could also reside in the 
smooth muscle cells of the vasculature and result from chronic exposure to 
AGEs.
Increased concentrations of IL-6 and CRP were both associated with 
lower insulin sensitivity, shown as a decrease in the eGDR, calculated by 
using a previously described modified formula (263). It is worth noting 
that by using the eGDR, we could show that insulin sensitivity worsened in 
parallel with the severity of renal disease in our patients, just as with IL-6. 
The positive correlation observed between IL-6 and triglycerides, and the 
negative correlation between IL-6 and HDL-cholesterol, further supports this 
observation. Thus, low-grade inflammation in patients with type 1 diabetes 
seems to be connected not only to the severity of proteinuria, but also to 
insulin sensitivity, as in type 2 diabetic patients with metabolic syndrome 
(180). Furthermore, these results were also in line with the data from the 
Pittsburgh Epidemiology of Diabetes Complication Study, showing that 
insulin resistance is indeed associated with overt nephropathy, although 
that study failed to include measurements of inflammatory markers (181). 
During resting conditions, roughly 15% to 35% of IL-6 derives from 
adipose tissue, and the majority derives from visceral adipose tissue (279-
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281). Given the strong relationship between IL-6 and WHR, we adjusted 
our results for WHR, but the adjustment failed to change the results. Thus, 
low-grade inflammation seems to be a key finding of diabetic nephropathy 
and could even be involved in the pathogenesis of insulin resistance in 
these patients. Such a view is supported by experimental data showing 
that IL-6 is capable of inducing insulin resistance in mouse hepatocytes and 
human hepatocarcinoma cell lines by interfering with insulin receptor signal 
transduction in these cells (282). IL-6 has also been shown to induce insulin 
resistance in adipocytes, and the expression of IL-6, like that of TNF-α, has 
been shown to be markedly elevated in the fat cells of insulin-resistant 
humans (283). Furthermore, regarding this induction of insulin resistance 
in adipocytes, IL-6 has been suggested to act in concert with TNF-α (283). 
Thus, low-grade inflammatory markers are associated with diabetic 
nephropathy in patients with type 1 diabetes. Whether low-grade 
inflammatory markers could serve in predicting initiation of the disease, 
and the progression of diabetic nephropathy needs to be assessed.
7.2.2 Mannan-binding lectin in patients with type 1 diabetes  
 and incipient or overt diabetic nephropathy (II)
In study II, we reported increased circulating concentrations of serum MBL 
in patients with type 1 diabetes and diabetic nephropathy. In contrast, we 
could observe no correlation between MBL and AER in patients with micro- 
or macroalbuminuria in this cross-sectional study, although this result could 
have been expected since such a correlation has been observed in patients 
with normal AER (198). However, HbA1c, a known risk factor for diabetic 
nephropathy, was independently related to the MBL levels. One possible 
explanation for these conflicting results could be the differences in glycemic 
control between our patient groups. 
The fact that MBL was unassociated with AER was in line with our 
finding that no relationship was observed between MBL and low-grade 
inflammatory markers IL-6 and CRP in this study, since we had previously 
shown an association between AER and these inflammatory markers in 
diabetic patients with incipient or overt nephropathy (273). One reason for 
the lack of correlation between MBL and inflammatory markers could be 
the simple fact that CRP may inhibit the production of MBL (284, 285). CRP 
has also been shown to modulate the cascade in which the complement 
regulatory protein H regulates MBL-initiated cytolysis, which may suggest 
some kind of coordination between MBL and CRP during the acute phase 
response (285). 
Even if we could confirm no independent relationship between MBL 
and insulin sensitivity as measured by using the eGDR in the multivariate 
analysis, there was a negative correlation between MBL and eGDR as well 
as between MBL and HDL-cholesterol in the univariate regression analysis, 
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suggesting that MBL may still be a marker of insulin resistance. 
In diabetic nephropathy, whether MBL plays an active role in the initial 
pathogenesis or acts as a progression promoter of an already existing 
disease remains unknown. An active role was suggested in an inception 
cohort study in which high serum MBL concentrations, measured three 
years after the diagnosis of diabetes, were associated with the development 
of incipient or overt diabetic nephropathy during a median follow-up of 
18 years (286). Furthermore, patients with diabetic nephropathy and high 
serum concentrations of MBL have been shown to carry genetic variants of 
the MBL gene that promote high MBL production (199). 
 On the other hand, MBL has been suggested to play an unfavourable 
role in other chronic kidney diseases such as IgA nephropathy and Henoch-
Schönlein purpura nehpritis. MBL binding to the IgA complex results in 
complement activation, and the deposition of MBL in association with 
IgA nephropathy was found in the mesangial area of the kidneys in a 
subpopulation of patients with this disease (201, 287-289). Furthermore, 
activation of the lectin pathway of the complement has, in some studies 
(201, 290), though not all (287, 288), been associated with more severe 
renal damage in IgA nephropathy. In Henoch-Schönlein purpura nephritis, 
MBL deposition has also been observed and has even been associated with 
increased progression of renal disease (291).
IgA1, the isoform of IgA deposited in the mesangium, is a heavily 
glycosylated molecule (292). Some have suggested that the difference 
between patients who have IgA with and without mesangial MBL deposition 
is based on differences in IgA glycosylation (290).
Whether MBL is also found in the diabetic kidney remains unknown, 
but due to chronic hyperglycemia, one can speculate that MBL ligands are 
present in the diabetic glomeruli, leading to mesangial deposition of MBL 
with deleterious effects. 
The mechanism could be that hyperglycemia stimulates the production 
of N-acetylglucosamine through the hexosamine pathway, and that as 
a consequence, an abundance of various secretory and cell membrane 
glycoproteins would be modified by N-linked glycosylation, thus enabling 
these proteins to become targets for MBL in the kidneys and in other target 
organs.
In conclusion, MBL concentrations are elevated in patients with type 1 
diabetes and diabetic nephropathy. Whether MBL also plays a pathogenetic 
role remains unknown, but its independent association with glycemic 
control raises the possibility that it may have deleterious effects. 
7.2.3 Adiponectin in patients with type 1 diabetes (III)
In healthy people, a high concentration of adiponectin was, at the time 
we planned this study, associated with lower risk for myocardial infarction 
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in men (222) and with lower incidence of type 2 diabetes in both sexes 
(293, 294). Given these observations, we expected to find a decrease in 
adiponectin concentrations in patients with diabetic nephropathy, who 
usually present with insulin resistance and an aberrant lipid profile. The 
demonstration of markedly increased serum concentrations of adiponectin 
in patients with type 1 diabetes and overt nephropathy and, further, that 
adiponectin was associated with renal insufficiency were thus novel findings 
in our study. We could observe no independent association between 
adiponectin and inflammatory markers in this patient population, which 
was in line with recent findings among ESRD patients on dialysis (231), but 
in contrast to findings among predialytic patients with ESRD (232). These 
contrasting observations may be due to the different patient populations. 
Patients with ESRD are presumably living in a different metabolic milieu than 
are patients with mildly impaired renal function, and they have presumably 
more interfering factors, such as polypharmacy and uremic toxins, which can 
impact adiponectin and inflammatory markers. Notably, in a cross-sectional 
analysis of Eurodiab Prospective Complications Study data, which included a 
reasonable number of patients with type 1 diabetes from normoalbuminuria 
to macroalbuminuria, adiponectin showed no association with CRP (295). 
Furthermore, a study in patients in the early stages of chronic nondiabetic 
kidney disease, showed no relationship between adiponectin and CRP (296). 
We found an association between adiponectin and WHR, but not 
between adiponectin and more direct indices of insulin resistance. Research 
has established that not all fat is equal. WHR has been widely used to 
investigate the relationship between regional adipose tissue distribution 
and metabolic profile, and has been associated with the amount of 
abdominal visceral adipose tissue measured by CT (297-299). Adipose tissue 
in the abdominal or visceral versus subcutaneous depot differs in cell size, 
metabolic activity, and potential role in insulin resistance. Visceral fat and 
large adipocytes, prominent features in obesity, are more pathogenic and 
are associated with low adiponectin levels (300-306). 
Some (307, 308), but not all (266, 309, 310) studies have suggested that 
antihypertensive medication, ACE inhibition, or angiotensin receptor blocker 
(ARB) treatment positively effect levels of adiponectin. In our study, all 
the patients with microalbuminuria underwent ACE inhibition, but even 
so, no significant difference in adiponectin concentrations was observed 
between patients with microalbuminuria and those with normoalbuminuria. 
If the increase in adiponectin was due to ACE inhibition, a significant rise 
in adiponectin concentrations would have been expected in patients with 
microalbuminuria also.
The collagenous domain of the adiponectin molecule has four conserved 
lysines that can be modified by both hydroxylation and glycosylation. 
Hydroxylation and glycosylation are believed to be critical for the 
three-dimensional structure of the adiponectin molecule by changing 
its configuration to a more biologically active form (207). Furthermore, 
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glycosylation is believed to be one of the major post-translational 
modifications of adiponectin (207). In patients with diabetes and constant 
hyperglycemia, the glycosylation process is probably altered, which could 
further modify the function of the adiponectin molecule. Consequently, 
a modified adiponectin molecule could result in a functional change in 
the essential hormonal feedback systems of the body (i.e. in the form 
of diminished negative feedback) and thereby increased adiponectin 
concentrations in diabetes.
Insulin resistance, a typical feature of nephropathy, is in patients 
with type 2 diabetes associated with suppressed/low serum adiponectin 
concentrations (215). Therefore, we would also have expected to find low 
serum adiponectin levels in patients with macroalbuminuria, an insulin-
resistant state in patients with type 1 diabetes also (181, 273, 311). One 
potential explanation for this finding would be renal insufficiency per se, 
which could stimulate adiponectin production or alternatively lead to a 
defect in the clearance of adiponectin. Both alternatives, either separately 
or together, would raise adiponectin concentrations. A defect in clearance 
is supported by the finding that plasma adiponectin concentrations are 
lower after successful kidney transplantation than they are before (233). 
Although the true mechanisms responsible for such an increase in circulating 
adiponectin in diabetic nephropathy remain unclear, one can speculate 
that adiponectin itself may play a role in mitigating the burden of vascular 
complications in diabetic nephropathy, as has been suggested in ESRD 
(312). Notably, adiponectin has been shown to play a role in endothelium-
dependent vasodilatation (313). Furthermore, some have suggested that 
adiponectin participates in the defence mechanisms of the endothelium by 
inhibiting the deleterious effects of tumor necrosis factor-α (217).
In our study, both AER and estimated GFR were independently associated 
with increased adiponectin concentrations in type 1 diabetic patients with 
nephropathy. Our results differ from those of previous studies, which 
failed to detect any association between GFR and adiponectin, even if 
the degree of proteinuria was positively associated with adiponectin in 
the first study (231), though not in the following study (232). The most 
plausible explanation is the inclusion of different patient populations as 
well as the number of patients with type 1 diabetes, which was significantly 
higher in our study than in the previous two studies. Notably, in a study 
of type 2 diabetic Pima Indians, adiponectin was associated with elevated 
serum creatinine and macroalbuminuria (314). In conclusion, serum 
adiponectin concentrations are elevated in patients with type 1 diabetes and 
nephropathy, and these levels are further associated with renal insufficiency. 
The reason why circulating adiponectin levels are high in these insulin-
resistant conditions, such as proteinuria and advanced nephropathy, remain 
unclear.
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7.2.4 α-defensin (-1, -2, and -3) in patients with type 1   
 diabetes and nephropathy 
α-defensin (-1, -2, and -3) was significantly higher in patients with 
macroalbuminuria than in those with either normo- or microalbuminuria. 
No difference in α-defensin serum concentrations was observed between 
the latter two groups. In addition, there was an independent relationship 
between kidney function, estimated by the Cockcroft–Gault formula, 
and α-defensin, suggesting an impact of renal insufficiency on circulating 
α-defensin levels. This suggestion is supported by earlier observations of 
peptide hormone metabolism in kidneys (315), and by observations that 
patients with diabetic nephropathy have a reduced capacity to degrade 
peptides (316-318). The production of α-defensin has until now proved 
uninducible, as is the production of β-defensin-2 and -3, by inflammatory 
mediators (242), which further supports the possible role of decreased renal 
degradation as the cause for increased serum concentrations of α-defensin 
in advanced diabetic nephropathy.
Our finding of an independent relationship between age and α-defensin 
was in line with the known age-related decline in GFR. 
We observed an association between α-defensin and inflammatory 
markers (CRP and IL-6) in the univariate association, but not in the 
multivariate analysis. Nor was there any association between α-defensin and 
MBL, even though chronic low-grade inflammation and the lectin pathway 
have both been associated with diabetic nephropathy, and are believed 
to play a role in the pathogenesis of diabetic nephropathy (273, 286, 319, 
320). Thus, α-defensin could be an independent novel marker of diabetic 
nephropathy. 
Notably, α-defensin was positively associated with cholesterol and 
negatively associated with HDL cholesterol, suggesting that α-defensin 
may play a role in the pathogenetic processes of atherosclerosis, a common 
phenomenon in patients with diabetic nephropathy. This suggestion is in 
line with observations showing that α-defensin stimulates the binding of 
lipoprotein (a) and low-density lipoprotein to vascular cells (256, 257); it is 
worth noting that α-defensin is abundantly present in the walls of human 
coronary arteries (321). In a recent prospective study of Danish patients with 
long-lasting (mean duration of diabetes 27 years) type 1 diabetes, α-defensin 
was associated with increased cardiovascular mortality during the ten-year 
follow-up (322). Notably, in that study, α-defensin levels were higher in 
patients with diabetic nephropathy than in those with normoalbuminuria, 
as in our study. 
In conclusion, serum α-defensin (-1, -2, and -3) concentrations are higher 
in patients with type 1 diabetes and diabetic nephropathy than in patients 
with either normo- or microalbuminuria. Whether the elevation in serum 
α-defensin plays a role in the pathogenesis of diabetic nephropathy or 
simply reflects changes in renal function must be resolved in further studies. 
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7.2.5 Adiponectin and the progression of diabetic   
 nephropathy (V)
Our observation that an elevated serum concentration of adiponectin at 
baseline may predict the progression from overt diabetic nephropathy to ESRD 
in patients with type 1 diabetes is a new finding. In contrast, we observed no 
differences in the serum adiponectin concentrations between progressors and 
non-progressors in patients with normo- and microalbuminuria. 
Our data thus contrast with the results of a previous study in which those 
patients who progressed from normo- to microalbuminuria exhibited higher 
adiponectin concentrations than did those who showed no progress (323). 
It is worth noting that we studied a substantially larger patient population 
(818 vs. 126 patients) with type 1 diabetes and normoalbuminuria, which may 
explain the observed difference. Furthermore, our patients were younger and 
had better glycemic control, but a higher BMI.
Notably, our observation also contrasted with an observation from the 
Modification of Diet in Renal Disease (MDRD) study (324). The MDRD study 
found no association between adiponectin and the progression of kidney 
disease, even when including those patients with moderate to advanced kidney 
disease. A plausible explanation for this discrepancy is probably the different 
patient populations. The patients in the MDRD study were substantially older 
and had a higher BMI, only 42 patients actually had diabetes, and none of 
them had type 1 diabetes.
As expected, most of our patients with type 1 diabetes and diabetic 
nephropathy were treated with an ACE inhibitor or an ARB, agents known to 
increase serum adiponectin in non-diabetic patients with essential hypertension 
(307). The great majority of the patients in the macroalbuminuric group 
were receiving ACE inhibitor treatment (n = 217), and only 25 patients were 
receiving ARB treatment. However, we observed no differences in adiponectin 
concentrations regardless of whether the patients were taking ACE inhibitors, 
an observation that is in line with the results of a recent study in which the 
authors observed no effects on the adiponectin concentration after adding 
the ACE inhibitor ramipril to the treatment of patients with type 2 diabetes 
and hypertension (309). Notably, in patients with type 1 diabetes, treatment 
with an ARB has been shown to increase the adiponectin concentration in 
a short-term study in nine normotensive male patients with type 1 diabetes 
and an AER in normal range (308). However, two other recent studies with 
substantially larger patient populations and patients of both genders showed 
no independent effect of an ACE inhibitor or an ARB on adiponectin levels. 
In the first of these studies (266), the patients receiving ACE inhibition had 
a slightly higher serum adiponectin concentration, but the difference was 
insignificant, and in the second study, treatment with an ACE inhibitor or 
an ARB correlated with adiponectin levels in the univariate, but not in the 
multivariate analysis (310). In our study, 75% of the progressors received ACE 
inhibition/ARB treatment in comparison with 84% of the non-progressors. This 
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small difference was statistically insignificant.
Taken together, these results indicate that at least ACE inhibitors have 
no dramatic effect on adiponectin levels in patients with type 1 diabetes. 
Whether this is also true for ARBs remains to be seen. Only 25 patients with 
macroalbuminuria received ARB treatment compared to 217 who received 
ACE inhibition. 
The reason for the elevated concentrations of adiponectin in the 
progressors from macroalbuminuria to ESRD remains unknown. Potential 
hypotheses include a compensatory response to vascular injury (231, 266, 295, 
312, 325, 326), the effects of subcutaneous insulin treatment (209), decreased 
clearance of adiponectin due to renal insufficiency (231, 233), and post-
translational glycosylational modifications (327, 328).
Importantly, glycosylation represents one of the major post-translational 
modifications of adiponectin, which, together with hydroxylation, is critical for 
the construction of the three-dimensional structure of the biologically active 
adiponectin molecule that regulates the formation of the high-molecular-
weight oligomeric adiponectin complex (207, 327, 328). Notably, even a 
relatively short period (72h) of high plasma glucose (15 mmol/l) reportedly 
increased production of the biologically highly active high–molecular-weight 
adiponectin when compared to normoglycemic conditions (5 mmol/l) (328). 
Whether this experimental observation in human adipose tissue culture also 
occurs in the clinical setting of patients with type 1 diabetes, macroalbuminuria, 
and chronic hyperglycemia remains unknown. However, some support for the 
hypothesis comes from the observation that our patients with type 1 diabetes 
and macroalbuminuria had “by definition” worse glycemic control than did 
the patients with normo- or microalbuminuria. In addition, adiponectin 
and glycemic control, as measured by HbA1c, were both associated with the 
progression of diabetic nephropathy. 
Whether decreased clearance of adiponectin due to renal insufficiency 
per se could trigger an increase in adiponectin concentrations is another 
possibility. A high concentration of plasma adiponectin has been shown to 
decrease after renal transplantation, which supports the role of adiponectin 
clearance for the high serum adiponectin concentrations observed in patients 
with macroalbuminuria (233). In a study of patients with type 2 diabetes 
and macroalbuminuria, however, enhanced production of adiponectin was 
considered a stronger determinant of serum adiponectin concentrations than 
a reduction in the renal clearance of adiponectin. This was based on a marked 
increase in both the serum and the urinary adiponectin levels in patients with 
overt diabetic nephropathy and on a positive correlation between serum 
adiponectin concentrations and urinary adiponectin excretion in all diabetic 
patients (329). Thus, renal insufficiency may not only affect the clearance of 
adiponectin, but also stimulate adiponectin production. 
Insulin has been shown either to stimulate (330, 331) adiponectin synthesis 
or to reduce it (225). Insulin has also been shown to stimulate adiponectin 
secretion from adipocytes (203, 332). During long-standing insulin treatment, 
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however, such as in patients with type 1 diabetes, insulin has been inversely 
associated with adiponectin levels (266, 295, 310, 333), a finding which 
is also enjoys the support of observations during a 5-h hyperinsulinemic-
euglycemic clamp study in patients with type 2 diabetes (226). In the clamp 
study, adiponectin levels decreased 20% after insulin administration in both 
lean and obese people as well as in patients with type 2 diabetes (226). In 
our study, surrogate measures of insulin sensitivity, such as the total insulin 
dose or the dose of insulin per kilogram of body weight, were both inversely 
associated with adiponectin concentrations, similar to what was observed in 
the prospective MDRD study (324). 
The effect of insulin on the level of adiponectin is also believed to be 
modified by hyperglycemia, since hyperglycemia can neutralize the negative 
effect of insulin on adiponectin concentrations (334). In this respect, it is 
noteworthy that in our study, the progressors from macroalbuminuria also 
had the worst glycemic control. 
In patients with type 1 diabetes and diabetic nephropathy, an increased 
concentration of adiponectin may in fact mitigate the micro- and 
macrovascular burden of diabetic nephropathy, thus acting as a compensatory 
response to the demands of the metabolic milieu and vascular injury (266, 295, 
326). In patients with type 1 diabetes and nephropathy and hyperglycemia, 
an increase in adiponectin could also serve as a mechanism to reduce 
hepatic gluconeogenesis. This is supported by the fact that the increase in 
adiponectin in patients with type 1 diabetes, and even more so in those with 
diabetic nephropathy, is due mainly to an increase in high-molecular-weight 
adiponectin (335). High-molecular-weight adiponectin is associated with the 
inhibition of liver gluconeogenesis, and further, the observed positive effect 
of adiponectin on glucose tolerance and insulin sensitivity is especially related 
to this isoform of adiponectin (205, 336-338). 
An increase of adiponectin in patients with type 1 diabetes and diabetic 
nephropathy could also be a counter-regulatory response to adiponectin 
resistance (339, 340). Such adiponectin resistance could result from altered 
adiponectin function due to glycosylation (207, 329). Consequently, a modified 
adiponectin molecule could lead to reduced negative feedback, and thus 
to higher adiponectin concentrations. An increase in serum adiponectin 
concentrations has also been suggested to reflect a dysfunction of the 
adiponectin receptors or to stem from a reduction in adiponectin receptor 
expression. This would decrease tissue adiponectin sensitivity, thus resembling 
situations in patients with low adiponectin concentrations, such as in type 2 
diabetes (341, 342). 
In conclusion, an increased adiponectin concentration is prognostic 
regarding the progression from overt diabetic nephropathy to ESRD in patients 
with type 1 diabetes.
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8. Summary and Conclusions
8.1 Summary
1. Low-grade inflammation is associated with diabetic nephropathy in 
patients with type 1 diabetes.
2. Mannan-binding lectin (MBL) is associated with diabetic nephropathy in 
patients with type 1 diabetes, but there is no association between MBL 
and low-grade inflammatory markers, nor any independent association 
between MBL and insulin resistance.
3.  Serum adiponectin is associated with renal function. Adiponectin is 
also associated with WHR as a marker of insulin resistance, but not 
independently with low-grade inflammatory markers or metabolic 
control.
4. α-defensin (-1, -2, and -3) is associated with renal function, total and HDL 
cholesterol, but not independently with low-grade inflammatory markers 
in patients with type 1 diabetes.
5. In patients with normo- or microalbuminuria, progressors and non-
progressors show no differences in baseline adiponectin concentrations, 
but, in contrast to this finding, adiponectin is an independent predictor 
of progression from macroalbuminuria to ESRD in patients with type 1 
diabetes.
8.2 Conclusions
All studied variables – low-grade inflammation, MBL, adiponectin, and 
α-defensin – were associated with diabetic nephropathy in our cross-
sectional studies. In contrast, however, MBL, adiponectin, and α-defensin on 
their own were unassociated with low-grade inflammatory markers. Further, 
α-defensin was unassociated with MBL, which may suggest that during the 
acute phase response, these different factors function in a coordinated 
fashion during the deleterious process of diabetic nephropathy. 
Which factors cause low-grade inflammation and increased serum MBL, 
adiponectin, and α-defensin concentrations in patients with type 1 diabetes 
and diabetic nephropathy remains unknown. Potential factors may include 
inheritance (genes), smoking, obesity, hyperglycemia, hyperlipidemia, and 
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a low level of physical activity. To support this suggestion, we could observe 
in our study that glycemic control, an atherosclerotic lipid profile, and WHR 
were associated with low-grade inflammation in a univariate analysis. In a 
multivariate analysis, however, only the duration of diabetes (as a measure 
of glycemic load), HDL-cholesterol, and AER proved to be independently 
associated with inflammation. Glycemic control, as measured by HbA1c, 
was the only variable independently associated with MBL, although in a 
univariate analysis, eGDR and HDL cholesterol were also associated with 
MBL. In addition to renal function, AER and WHR were independently 
associated with adiponectin, whereas age, systolic blood pressure, HDL- 
and total cholesterol were independently associated with α-defensin in our 
cross-sectional study. Notably, all these factors, except genes and age, are 
modifiable by changes in lifestyle or a targeted medication or both. In our 
follow-up study, elevated serum adiponectin levels at baseline predicted 
progression from macroalbuminuria to ESRD independently of renal 
function at baseline. This observation does not preclude adiponectin as a 
positive factor during the process of diabetic nephropathy, however, since 
the increase in serum adiponectin concentrations may still be a mechanism 
by which the body compensates for the demands created by the diabetic 
milieu. 
In order to be able to prevent diabetic nephropathy and to improve the 
prognosis of our patients, detecting any signs of problems as early as possible 
is vital. Clearly, this will pose a real challenge not only for the patients, but 
also for the health care personnel. Markers of inflammation may represent 
early warning signs if combined with other relevant characteristic features 
associated with the development of diabetic nephropathy. Consequently, 
future studies should combine different markers of inflammation with a 
variety of clinical variables, such as various components of the metabolic 
syndrome for instance, to possibly enable more accurate and sufficiently 
early risk detection for our patients with diabetes. We foresee that a new 
risk score, similar to what has already been available for many years for 
the prevention of myocardial infarction, could serve as a call to action both 
in the sense of prevention and in the treatment of diabetic nephropathy.
Innate immune system and adiponectin in diabetic nephropathy in type 1 diabetes 55
9. Acknowledgements
This study was carried out at the Folkhälsan Institute of Genetics, Folkhälsan 
Research Center at the University of Helsinki and at the Division of 
Nephrology, Department of Medicine at the Helsinki University Central 
Hospital. 
I wish to express my deep gratitude to the heads of these institutes for 
providing with me excellent research facilities during my study years: Docent 
Per-Henrik Groop, Professor Anna-Elina Lehesjoki, Docent Eero Honkanen, 
and Professor Carola Grönhagen-Riska. 
I am greatly indebted to Docent Per-Henrik Groop, who was my supervisor 
and founder of the FinnDiane Study Group. His knowledge of diabetes 
and diabetic nephropathy and its associations with all other diabetic 
complications have been the true basis for this study. His encouraging 
attitude and energy were needed to carry out the work, though he never 
mentioned the long hours spent finalizing the manuscripts both with regard 
to their scientific content and proper use of written language.
I am especially greatful to Carol Forsblom, my long-time friend who 
has supported and helped me already at the beginning of this study and 
throughout all the study periods. He has always made time to discuss the 
study and its problems without ever mentioning his statistical skills. His 
encouragement and new ideas have been of great importance to me when 
I try to find a solution to a problem. 
I thank our chemist, Anna-Maija Teppo, for those long discussions about 
inflammation and which inflammation pathways would be most critical to 
diabetic nephropathy. We could not have performed these studies without 
her profound knowledge in developing new assays. 
I sincerely thank my reviewers, Professor Timo Strandberg and Docent 
Ilkka Tikkanen, for their valuable critical and constructive comments during 
their review of the manuscript. 
I am also grateful to Stephen Stalter for his help with author-editing 
the manuscript. 
I also thank my collaborators and coauthors for their valuable 
contributions to this work. At FinnDiane, Johan Fagerudd, Kim Pettersson-
Fernholm, Lena Thorn, Johan Wadén, Milla Rosengård-Bärlund, Outi 
Heikkilä, Kustaa Hietala, and Daniel Gordin are warmly thanked for their 
support over the years. I thank my external collaborator, Docent Pertti 
Ebeling, for his valuable thoughts about MBL in general and in relation to 
diabetic complications. 
I sincerely thank Professor Allan Flyvbjerg, Lecturer Jan Frystyk, as well 
as Drs Troels Krarup-Hansen, Stefan Thiel, and Lise Tarnow for all the 
discussions and new ideas about different possible pathways and players 
in the field of diabetic nephropathy. The in-house developed assays in 
Aarhus, Denmark enabled us to measure several new potential actors in 
9  Acknowledgements56
chronic inflammation. This is a true example of good international scientific 
collaboration. It has really been a priviledge to work in the FinnDiane 
Study group, and I wish to acknowledge my fellow scientists in our group 
for their help and for creating an enjoyable/encouraging atmosphere to 
work in through all these years: Jenny Söderlund, Nina Tolonen, Aila Ahola, 
Ville Mäkinen, Anna Hoverfelt, Kustaa Hietala, Markku Lehto, Janne Kytö, 
Pekka Ihalmo, Maija Wessman, Aino Soro-Paavonen, Maija Feodoroff, Laura 
Kyllönen, Valma Harjutsalo, and many more. 
I also wish to thank FinnDiane Study nurses Anna Sandelin, Sinikka 
Lindh, Jaana Tuomikangas, and Tarja Vesisenaho, all of whom have been 
instrumental in arranging appointments with patients in their holistic care. 
Maikki Parkkonen is warmly acknowledged for her valuable advice 
regarding laboratory methods as well as for her efficient, skillful technical 
assistance. 
This work has benefited from the financial support of the Folkhälsan 
Research Foundation, the Wilhelm and Else Stockmann Foundation, the 
Liv och Hälsa Foundation, the Biodemicum Helsinki Foundation, and the 
European Commission. 
I am grateful to all patients and their family members in Finland for 
participating in the FinnDiane study, and, in so doing, for enabling the 
beginning and continuation of our study. 
I sincerely thank Docent Erkki O. Jänkälä, Docent Hilkka Hiekkala, and 
Professor Tero Kangas for their help, advice, and encouraging attitude 
toward the future. 
I would also like to thank philosopher Arkkiatri Risto Pelkonen, a fine 
example of how a doctor should take holistic care of his patients, especially 
those with diabetes.
Finally, I owe my deepest gratitude to my wife Elina, daughters Anna 
and Maria, and to my mother Sirkka, sister Marjatta, brother Matti, and 
to my aunt Anna-Liisa and uncle Aarne. I also warmly appreciate the 
encouragement of the parents of my wife, Kaisa and Jaakko, and as well 
as that of her brothers and sisters. Thank you all! You have truly made this 
possible!
Innate immune system and adiponectin in diabetic nephropathy in type 1 diabetes 57
Appendix
The Finnish Diabetic Nephropathy Study Centers
Anjalankoski Health Center: S. Koivula, T. Uggeldahl
Central Finland Central Hospital, Jyväskylä: T. Forslund, A. Halonen, A. Koistinen,  
P. Koskiaho, M. Laukkanen, J. Saltevo, M. Tiihonen
Central Hospital of Åland Islands, Mariehamn: M. Forsen, H. Granlund, A.-C. Jonsson, 
B. Nyroos
Central Hospital of Kanta-Häme, Hämeenlinna: P. Kinnunen, A. Orvola, T. Salonen,  
A. Vähänen
Central Hospital of Kymenlaakso, Kotka: R. Paldanius, M. Riihelä, L. Ryysy
Central Hospital of Länsi-Pohja,Kemi: H. Laukkanen, P. Nyländen, A. Sademies
Central Ostrobothnian Hospital District, Kokkola: S. Anderson, B. Asplund,  
U. Byskata, P. Liedes, M. Kuusela, T. Virkkala
City of Espoo Health Center, Espoonlahti: A. Nikkola, E. Ritola, Tapiola, M. Niska,  
H. Saarinen. Samaria: E. Oukko-Ruponen, T. Virtanen, Viherlaakso: 
A. Lyytinen
City of Helsinki Health Center, Puistola: H. Kari, T. Simonen. Suutarila: A. Kaprio,  
J. Kärkkäinen, B. Rantaeskola. Töölö: P. Kääriäinen, J. Haaga, A-L. Pietiläinen
City of Hyvinkää Health Center: S. Klemetti, T. Nyandoto, E. Rontu, S. Satuli-Autere
City of Vantaa Health Center: Korso: R. Toivonen, H. Virtanen. Länsimäki: R. Ahonen, 
M. Ivaska-Suomela, A. Jauhiainen. Martinlaakso: M. Laine, T. Pellonpää,  
R. Puranen. Myyrmäki: A. Airas, J. Laakso, K. Rautavaara. Rekola: M. Erola,  
E. Jatkola. Tikkurila: R. Lönnblad, A. Malm, J. Mäkelä, E. Rautamo
Heinola Health Center: P. Hentunen, J. Lagerstam
Helsinki University Central Hospital, Department of Herttoniemi Hospital, Helsinki: 
V. Sipilä
Hospital of Lounais-Häme, Forssa: T. Kalliomäki, J. Koskelainen, R. Nikkanen,  
N. Savolainen, H. Sulonen, E. Valtonen
Iisalmi Hospital: E. Toivanen
Jokilaakso Hospital, Jämsä: A. Parta, I. Pirttiniemi
Jorvi Hospital, Helsinki University Central Hospital: S. Aranko, S. Ervasti,  
R. Kauppinen-Mäkelin, A. Kuusisto, T. Leppälä, K. Nikkilä, L. Pekkonen
Jyväskylä Health Center, Kyllö: K. Nuorva, M. Tiihonen
Kainuu Central Hospital, Kajaani: S. Jokelainen, P. Kemppainen, A-M. Mankinen,  
M. Sankari
Kerava Health Center: H. Stuckey, P. Suominen
Kirkkonummi Health Center: A. Lappalainen, M. Liimatainen, J. Santaholma
Kivelä Hospital, Helsinki : A. Aimolahti, E. Huovinen
Koskela Hospital, Helsinki: V. Ilkka, M. Lehtimäki
Kotka Health Center: E. Pälikkö-Kontinen, A. Vanhanen
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Kouvola Health Center: E. Koskinen, T. Siitonen
Kuopio University Hospital: E. Huttunen, R. Ikäheimo, P. Karhapää, P. Kekäläinen,  
M. Laakso, T. Lakka, E. Lampainen, L. Moilanen, L. Niskanen, U. Tuovinen,  
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Lapland Central Hospital, Rovaniemi: L. Hyvärinen, S. Severinkangas, T. Tulokas
Lappeenranta Health Center: P. Linkola, I. Pulli
Lohja Hospital: T. Granlund, M. Saari, T. Salonen
Länsi-Uusimaa Hospital, Tammisaari: I.-M. Jousmaa, J. Rinne
Loimaa Health Center: A. Mäkelä, P. Eloranta
Malmi Hospital, Helsinki: H. Lanki, S. Moilanen, M. Tilly-Kiesi
Mikkeli Central Hospital: A. Gynther, R. Manninen, P. Nironen, M. Salminen,, T. 
Vänttinen
Mänttä Regional Hospital: I. Pirttiniemi, A-M. Hänninen
North Karelian Hospital, Joensuu: U-M. Henttula, P. Kekäläinen, M. Pietarinen,  
A. Rissanen, M. Voutilainen
Nurmijärvi Health Center: A. Burgos, K. Urtamo
Oulaskangas Hospital, Oulainen: E. Jokelainen, P.-L. Jylkkä, E. Kaarlela, J. Vuolaspuro
Oulu Health Center: L. Hiltunen, R. Häkkinen, S. Keinänen-Kiukaanniemi
Oulu University Hospital: R. Ikäheimo
Päijät-Häme Central Hospital: H. Haapamäki, A. Helanterä, S. Hämäläinen,  
V. Ilvesmäki, H. Miettinen
Palokka Health Center: P. Sopanen, L. Welling
Pieksämäki Hospital: V. Javtsenko, M. Tamminen
Pietarsaari Hospital: M-L. Holmbäck, B. Isomaa, L. Sarelin
Pori City Hospital: P. Ahonen, P. Merensalo, K. Sävelä
Porvoo Hospital: M. Kallio, B. Rask, S. Rämö
Raahe Hospital: A. Holma, M. Honkala, A. Tuomivaara, R. Vainionpää
Rauma Hospital: K. Laine, K. Saarinen, T. Salminen
Riihimäki Hospital: P. Aalto, E. Immonen, L. Juurinen
Salo Hospital: A. Alanko, J. Lapinleimu, P. Rautio, M. Virtanen
Satakunta Central Hospital, Pori: M. Asola, M. Juhola, P. Kunelius, M.-L. Lahdenmäki,
P.Pääkkönen, M. Rautavirta
Savonlinna Central Hospital: T. Pulli, P. Sallinen, M. Taskinen, E. Tolvanen,  
H. Valtonen, A. Vartia
Seinäjoki Central Hospital: E. Korpi-Hyövälti, T. Latvala, E. Leijala
South Karelia Central Hospital, Lappeenranta: T. Ensala, E. Hussi, R. Härkönen, 
U. Nyholm, J. Toivanen
Tampere Health Center: A. Vaden, P. Alarotu, E. Kujansuu, H. Kirkkopelto-Jokinen,  
M. Helin, S. Gummerus, L. Calonius, T. Niskanen, T. Kaitala, T. Vatanen
Tampere University Hospital: I. Ala-Houhala, T. Kuningas, P. Lampinen, M. Määttä, 
H. Oksala, T. Oksanen, K. Salonen, H. Tauriainen, S. Tulokas
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Tiirismaa Health Center, Hollola: T. Kivelä, L. Petlin, L. Savolainen
Turku Health Center: I. Hämäläinen, H. Virtamo, M. Vähätalo
Turku University Central Hospital: K. Breitholz, R. Eskola, K. Metsärinne, U. Pietilä,  
P. Saarinen, R. Tuominen, S. Äyräpää
Vaajakoski Health Center: K. Mäkinen, P. Sopanen
Valkeakoski Regional Hospital: S. Ojanen, E. Valtonen, H. Ylönen, M. Rautiainen,  
T. Immonen
Vammala Regional Hospital: I. Isomäki, R. Kroneld, M. Tapiolinna-Mäkelä
Vasa Central Hospital: S. Bergkulla, U. Hautamäki, V.-A. Myllyniemi, I. Rusk, K. Lahti
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